WO2015086727A2 - New prognostic method for patients suffering of a cancer - Google Patents
New prognostic method for patients suffering of a cancer Download PDFInfo
- Publication number
- WO2015086727A2 WO2015086727A2 PCT/EP2014/077335 EP2014077335W WO2015086727A2 WO 2015086727 A2 WO2015086727 A2 WO 2015086727A2 EP 2014077335 W EP2014077335 W EP 2014077335W WO 2015086727 A2 WO2015086727 A2 WO 2015086727A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- plcyl
- cll
- expression level
- cells
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 88
- 201000011510 cancer Diseases 0.000 title claims abstract description 68
- 238000000034 method Methods 0.000 title claims abstract description 56
- 230000014509 gene expression Effects 0.000 claims abstract description 112
- 238000011282 treatment Methods 0.000 claims abstract description 45
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims abstract description 30
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims abstract description 30
- 239000000556 agonist Substances 0.000 claims abstract description 16
- 238000000338 in vitro Methods 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 134
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 128
- 150000001413 amino acids Chemical group 0.000 claims description 69
- 150000001875 compounds Chemical class 0.000 claims description 21
- 230000001225 therapeutic effect Effects 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 13
- 238000004393 prognosis Methods 0.000 claims description 13
- 230000004083 survival effect Effects 0.000 claims description 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 120
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 120
- 210000004027 cell Anatomy 0.000 description 84
- 108090000623 proteins and genes Proteins 0.000 description 73
- 102000004169 proteins and genes Human genes 0.000 description 66
- 229940024606 amino acid Drugs 0.000 description 65
- 102000004196 processed proteins & peptides Human genes 0.000 description 62
- 235000018102 proteins Nutrition 0.000 description 61
- 235000001014 amino acid Nutrition 0.000 description 55
- 238000003782 apoptosis assay Methods 0.000 description 46
- 230000005522 programmed cell death Effects 0.000 description 46
- 210000003719 b-lymphocyte Anatomy 0.000 description 45
- 108010017447 4N1K peptide Proteins 0.000 description 27
- 239000000523 sample Substances 0.000 description 21
- 235000018977 lysine Nutrition 0.000 description 20
- 108020004999 messenger RNA Proteins 0.000 description 20
- 150000007523 nucleic acids Chemical class 0.000 description 20
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 19
- 239000004472 Lysine Substances 0.000 description 19
- 239000013604 expression vector Substances 0.000 description 19
- 230000001404 mediated effect Effects 0.000 description 19
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 208000032839 leukemia Diseases 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- -1 phospholipid phosphatidylinositol 4,5-bisphosphate Chemical class 0.000 description 14
- 102000011727 Caspases Human genes 0.000 description 13
- 108010076667 Caspases Proteins 0.000 description 13
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 239000002202 Polyethylene glycol Substances 0.000 description 12
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 12
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 12
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 239000004475 Arginine Substances 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 230000001275 ca(2+)-mobilization Effects 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 8
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000003119 immunoblot Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 7
- 229960005420 etoposide Drugs 0.000 description 7
- 229930182817 methionine Natural products 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102100029968 Calreticulin Human genes 0.000 description 6
- 108090000549 Calreticulin Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 6
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 6
- 108091027967 Small hairpin RNA Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 238000007385 chemical modification Methods 0.000 description 6
- 239000007850 fluorescent dye Substances 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 5
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 5
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 5
- 206010061424 Anal cancer Diseases 0.000 description 5
- 208000007860 Anus Neoplasms Diseases 0.000 description 5
- 206010004593 Bile duct cancer Diseases 0.000 description 5
- 206010005003 Bladder cancer Diseases 0.000 description 5
- 206010005949 Bone cancer Diseases 0.000 description 5
- 208000018084 Bone neoplasm Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 5
- 208000005024 Castleman disease Diseases 0.000 description 5
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 206010014733 Endometrial cancer Diseases 0.000 description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 description 5
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 5
- 208000017604 Hodgkin disease Diseases 0.000 description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 5
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 5
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 5
- 208000007766 Kaposi sarcoma Diseases 0.000 description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 description 5
- 206010023825 Laryngeal cancer Diseases 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 208000032271 Malignant tumor of penis Diseases 0.000 description 5
- 206010027406 Mesothelioma Diseases 0.000 description 5
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 5
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 5
- 206010029260 Neuroblastoma Diseases 0.000 description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 5
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 5
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- 208000002471 Penile Neoplasms Diseases 0.000 description 5
- 206010034299 Penile cancer Diseases 0.000 description 5
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 5
- 208000007452 Plasmacytoma Diseases 0.000 description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 5
- 201000000582 Retinoblastoma Diseases 0.000 description 5
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 5
- 206010061934 Salivary gland cancer Diseases 0.000 description 5
- 208000000453 Skin Neoplasms Diseases 0.000 description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 208000024313 Testicular Neoplasms Diseases 0.000 description 5
- 206010057644 Testis cancer Diseases 0.000 description 5
- 208000000728 Thymus Neoplasms Diseases 0.000 description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 description 5
- 206010047741 Vulval cancer Diseases 0.000 description 5
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 5
- 230000001919 adrenal effect Effects 0.000 description 5
- 201000006966 adult T-cell leukemia Diseases 0.000 description 5
- 201000011165 anus cancer Diseases 0.000 description 5
- 208000026900 bile duct neoplasm Diseases 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 201000000220 brain stem cancer Diseases 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 230000001964 calcium overload Effects 0.000 description 5
- 201000007455 central nervous system cancer Diseases 0.000 description 5
- 201000010881 cervical cancer Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 208000006990 cholangiocarcinoma Diseases 0.000 description 5
- 230000001054 cortical effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 201000010175 gallbladder cancer Diseases 0.000 description 5
- 206010017758 gastric cancer Diseases 0.000 description 5
- 201000009277 hairy cell leukemia Diseases 0.000 description 5
- 201000006866 hypopharynx cancer Diseases 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 201000010982 kidney cancer Diseases 0.000 description 5
- 206010023841 laryngeal neoplasm Diseases 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 208000025113 myeloid leukemia Diseases 0.000 description 5
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 5
- 201000005443 oral cavity cancer Diseases 0.000 description 5
- 229960003104 ornithine Drugs 0.000 description 5
- 201000006958 oropharynx cancer Diseases 0.000 description 5
- 201000002528 pancreatic cancer Diseases 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 201000002511 pituitary cancer Diseases 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 201000000849 skin cancer Diseases 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- 201000003120 testicular cancer Diseases 0.000 description 5
- 201000009377 thymus cancer Diseases 0.000 description 5
- 201000002510 thyroid cancer Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 201000005112 urinary bladder cancer Diseases 0.000 description 5
- 206010046766 uterine cancer Diseases 0.000 description 5
- 206010046885 vaginal cancer Diseases 0.000 description 5
- 208000013139 vaginal neoplasm Diseases 0.000 description 5
- 201000005102 vulva cancer Diseases 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 101150080074 TP53 gene Proteins 0.000 description 4
- 108010046722 Thrombospondin 1 Proteins 0.000 description 4
- 102100036034 Thrombospondin-1 Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 150000003857 carboxamides Chemical group 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 108700025694 p53 Genes Proteins 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- PTXMQRGGKNVOAK-YFKPBYRVSA-N (2s)-6-amino-2-(2-diazohydrazinyl)hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NN=[N+]=[N-] PTXMQRGGKNVOAK-YFKPBYRVSA-N 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- RRWZZMHRVSMLCT-UHFFFAOYSA-N 2-(butylazaniumyl)acetate Chemical compound CCCCNCC(O)=O RRWZZMHRVSMLCT-UHFFFAOYSA-N 0.000 description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102100026031 Beta-glucuronidase Human genes 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 3
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 3
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000014384 Type C Phospholipases Human genes 0.000 description 3
- 108010079194 Type C Phospholipases Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 150000001576 beta-amino acids Chemical class 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 150000004985 diamines Chemical class 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000006676 mitochondrial damage Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- NMDDZEVVQDPECF-LURJTMIESA-N (2s)-2,7-diaminoheptanoic acid Chemical compound NCCCCC[C@H](N)C(O)=O NMDDZEVVQDPECF-LURJTMIESA-N 0.000 description 2
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 2
- 102100030389 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2 Human genes 0.000 description 2
- 102100038366 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 Human genes 0.000 description 2
- 102100026205 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 Human genes 0.000 description 2
- YJIYWYAMZFVECX-UHFFFAOYSA-N 2-[N-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetic acid acetyloxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O YJIYWYAMZFVECX-UHFFFAOYSA-N 0.000 description 2
- DDOQBQRIEWHWBT-UHFFFAOYSA-N 2-azaniumyl-4-phosphonobutanoate Chemical compound OC(=O)C(N)CCP(O)(O)=O DDOQBQRIEWHWBT-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 102000002804 Ataxia Telangiectasia Mutated Proteins Human genes 0.000 description 2
- 101150065175 Atm gene Proteins 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 2
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102100029855 Caspase-3 Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000583066 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2 Proteins 0.000 description 2
- 101000605565 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 Proteins 0.000 description 2
- 101000691599 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 Proteins 0.000 description 2
- 101000975428 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 1 Proteins 0.000 description 2
- 101000975421 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 2 Proteins 0.000 description 2
- 101000975401 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 3 Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102100024039 Inositol 1,4,5-trisphosphate receptor type 1 Human genes 0.000 description 2
- 102100024037 Inositol 1,4,5-trisphosphate receptor type 2 Human genes 0.000 description 2
- 102100024035 Inositol 1,4,5-trisphosphate receptor type 3 Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102000004094 Stromal Interaction Molecule 1 Human genes 0.000 description 2
- 108090000532 Stromal Interaction Molecule 1 Proteins 0.000 description 2
- 108010030731 Stromal Interaction Molecule 2 Proteins 0.000 description 2
- 102100035562 Stromal interaction molecule 2 Human genes 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 206010063092 Trisomy 12 Diseases 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 150000001669 calcium Chemical class 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229960001987 dantrolene Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 108010004034 stable plasma protein solution Proteins 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- HTFFMYRVHHNNBE-YFKPBYRVSA-N (2s)-2-amino-6-azidohexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCN=[N+]=[N-] HTFFMYRVHHNNBE-YFKPBYRVSA-N 0.000 description 1
- OOBJCYKITXPCNS-REWPJTCUSA-N (3s)-5-(2,6-difluorophenoxy)-3-[[(2s)-3-methyl-2-(quinoline-2-carbonylamino)butanoyl]amino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)COC1=C(F)C=CC=C1F OOBJCYKITXPCNS-REWPJTCUSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- DAYKWVVEINTEQW-UHFFFAOYSA-N 1-(9h-fluoren-9-ylmethyl)piperidine Chemical group C12=CC=CC=C2C2=CC=CC=C2C1CN1CCCCC1 DAYKWVVEINTEQW-UHFFFAOYSA-N 0.000 description 1
- CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 1
- 125000000134 2-(methylsulfanyl)ethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])[*] 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GVDJEHMDNREMFA-UHFFFAOYSA-N 3,3,3-trifluoro-2-oxopropanoic acid Chemical compound OC(=O)C(=O)C(F)(F)F GVDJEHMDNREMFA-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 101800000267 CD40 ligand, soluble form Proteins 0.000 description 1
- 102400000432 CD40 ligand, soluble form Human genes 0.000 description 1
- 101000975407 Caenorhabditis elegans Inositol 1,4,5-trisphosphate receptor itr-1 Proteins 0.000 description 1
- 102100039319 Calcium release-activated calcium channel protein 1 Human genes 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- 102000047934 Caspase-3/7 Human genes 0.000 description 1
- 108700037887 Caspase-3/7 Proteins 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101000975393 Drosophila melanogaster Inositol 1,4,5-trisphosphate receptor Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000745520 Homo sapiens Calcium release-activated calcium channel protein 1 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101001122471 Homo sapiens Protein orai-3 Proteins 0.000 description 1
- 101000591205 Homo sapiens Receptor-type tyrosine-protein phosphatase mu Proteins 0.000 description 1
- 101000707567 Homo sapiens Splicing factor 3B subunit 1 Proteins 0.000 description 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108700001097 Insect Genes Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700005443 Microbial Genes Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100243350 Mus musculus Pecam1 gene Proteins 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 1
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700027852 ORAI2 Proteins 0.000 description 1
- 101150002636 ORAI2 gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108700036941 PKHB1 peptide Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 229940122985 Peptide agonist Drugs 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010056751 Phospholipase C gamma Proteins 0.000 description 1
- 102000004422 Phospholipase C gamma Human genes 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100027134 Protein orai-2 Human genes 0.000 description 1
- 102100027135 Protein orai-3 Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100034090 Receptor-type tyrosine-protein phosphatase mu Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 229930001406 Ryanodine Natural products 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 102100031711 Splicing factor 3B subunit 1 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- 102000037089 Uniporters Human genes 0.000 description 1
- 108091006293 Uniporters Proteins 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000007120 differential activation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000004847 durcupan Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 150000002669 lysines Chemical group 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- ZHOBJWVNWMQMLF-UHFFFAOYSA-N n,n-bis(prop-2-ynyl)prop-2-yn-1-amine Chemical compound C#CCN(CC#C)CC#C ZHOBJWVNWMQMLF-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- JJSYXNQGLHBRRK-SFEDZAPPSA-N ryanodine Chemical compound O([C@@H]1[C@]([C@@]2([C@]3(O)[C@]45O[C@@]2(O)C[C@]([C@]4(CC[C@H](C)[C@H]5O)O)(C)[C@@]31O)C)(O)C(C)C)C(=O)C1=CC=CN1 JJSYXNQGLHBRRK-SFEDZAPPSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NBAOBNBFGNQAEJ-UHFFFAOYSA-M tetramethylrhodamine ethyl ester perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C21 NBAOBNBFGNQAEJ-UHFFFAOYSA-M 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000010246 ultrastructural analysis Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to an in vitro method for classifying a patient suffering from cancer comprising the steps consisting of i) determining the expression level of PLCγl in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing the stage of the patient according to the expression level of PLCγl. The invention also relates to an agonist of CD47 receptor for use in the treatment of patient suffering of a cancer with a high expression level of PLCγ.
Description
NEW PROGNOSTIC METHOD FOR PATIENTS SUFFERING OF A CANCER
FIELD OF THE INVENTION:
The present invention relates to an in vitro method for classifying a patient suffering from cancer comprising the steps consisting of i) determining the expression level of PLCyl in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing the stage of the patient according to the expression level of PLCyl .
The invention also relates to a agonist of the CD47 receptor for use in the treatment of patient suffering of a cancer with a high expression level of PLCy.
BACKGROUND OF THE INVENTION:
Chronic lymphocytic leukemia (CLL), a human malignancy caused by an imbalance between proliferation and programmed cell death (PCD) [N. Chiorazzi et al, 2003], is the most common form of leukemia in adults. CLL is characterized by an accumulation of monoclonal B cells (CD20+, CD5+, and CD23+) in the peripheral blood, bone marrow, and secondary lymphoid organs that leads to the progressive failure of the immune and hematopoietic systems. CLL prognosis is dependent on clinical staging and biological markers like the IGHV status, cytogenetic abnormalities, expression of proteins such as CD38 or ZAP-70, and NOTCH 1 or SF3B1 mutations. Despite intense research and pharmaceutical development, there remains an unmet medical need for CLL. Indeed, 15-25% of patients remain or become refractory to the current chemotherapeutics [J. G. Gribben, 2010]. Moreover, patients with dysfunction relevant to TP53 gene (-7-10%) require a specific aggressive therapy that often yields a negative issue [H. Dohner et al, 2000]. It is therefore of highest interest to find original approaches in order to overcome CLL refractoriness.
From this perspective, CD47 appears to be a target of high therapeutic potential. CD47, a cell surface receptor that binds to signal regulatory protein a (SIRPa) and thrombospondin-1 (TSP1), serves as a marker of self and participates in the regulation of the cellular responses to stress. The binding of CD47 either to SIRPa or TSP1 provides two anticancer strategies. On the one hand, antibodies targeting CD47 or SIRPa, recombinant SIRPa or TSP1 -derived proteins promotes phagocytosis and tumor cell elimination by
disruption of the CD47-SIRPa interaction and/or induction of Fc-dependent mechanisms (e.g., ADCC or CDC) or PCD [X. W. Zhao et al, 2012]. On the other hand, the binding of CD47 to 4N1K, a decapeptide derived from the TSPl C-terminal domain, directly kills tumor cells [V. Mateo et al, 1999]. The latter strategy is underused but appears especially relevant.
SUMMARY OF THE INVENTION:
For a therapeutic purpose against CLL, the inventors have developed new peptides like PKHB1, a novel human serum- stable TSPl -derived decapeptide that links CD47 and kills primary CLL cells, including those from drug-resistant patients. During their investigations, the inventors show that the cytotoxic effect of the developed peptides and especially PKHB1 passes through the induction of a caspase-independent PCD pathway mediated by the sustained activation of phospholipase C gamma-1 (PLCyl), a signal transduction protein that they found over-expressed in CLL. PLCyl over- activation provoked endoplasmic reticulum (ER)-stress, Ca2+ overload, mitochondrial damage, calreticulin exposure, and PCD in CLL. The inventors concluded that the measure of the expression level of the PLCyl protein could be used in the prognostic of the gravity of patient suffering a cancer and especially CLL. The measurement of the expression level of the PLCyl protein may also be used as a therapeutic companion test. Moreover, the inventors show that inhibition of the PLCyl protein and its down-regulation abolishes CD47-mediated killing.
Thus, the invention relates to an in vitro method for classifying a patient suffering from cancer comprising the steps consisting of i) determining the expression level of PLCyl in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing the stage of the patient according to the expression level of PLCyl .
The invention also relates to an agonist of CD47 receptor for use in the treatment of patient suffering of a cancer with a high expression level of PLCy.
The invention also relates to a compound which active the PLCyl for use in the treatment of cancer.
DETAILED DESCRIPTION OF THE INVENTION:
Classifying and Predicting methods
The invention relates to an in vitro method for classifying a patient suffering from cancer comprising the steps consisting of i) determining the expression level of PLCyl in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing the stage of the patient according to the expression level of PLCyl .
The invention also relates to an in vitro method for the prognosis of the survival time of a patient suffering from cancer comprising the steps consisting of i) determining the expression level of PLCyl in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good outcome prognosis when the expression level is lower than the predetermined reference value and a poor outcome prognosis when the expression level is higher than the predetermined reference value.
The invention also relates to an in vitro method for the diagnosis of the severity of a cancer comprising the steps consisting of i) determining the expression level of PLCyl in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good diagnosis when the expression level is lower than the predetermined reference value and a poor diagnosis when the expression level is higher than the predetermined reference value.
As used herein, the term "PLCyl" has its general meaning in the art and denotes an enzyme, which cleaves the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into diacyl glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). An exemplary sequence for human PLCyl protein is deposited in NCBI (NM 002660.2).
In a one embodiment, the cancer is selected form the group consisting of adrenal cortical cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain and central nervous system cancer, breast cancer, Castleman disease, cervical cancer, colorectal cancer, endometrial cancer, oesophagus cancer, gallbladder cancer, gastrointestinal carcinoid tumors, Hodgkin's disease, non-Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, laryngeal and hypopharyngeal cancer, liver cancer, lung cancer, mesothelioma, plasmacytoma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cavity and oropharyngeal cancer, ovarian cancer, pancreatic cancer, penile cancer, pituitary cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer,
stomach cancer, testicular cancer, thymus cancer, thyroid cancer, vaginal cancer, vulvar cancer, and uterine cancer.
In another particular embodiment, cancer is selected fro me thr group consisting of leukemia, acute lymphoblastic leukemia, B-chronic lymphocytic leukemia, hairy-cell leukemia, adult T-cell leukemia, prolymophocytic leukaemia of T-cell type or myeloid leukaemia.
In one embodiment, the leukemia is a B-chronic lymphocytic leukemia (CLL).
In a particular embodiment, the CLL is a refractory CLL. In a particular embodiment, the invention relates to an in vitro method for classifying a patient suffering from a CLL comprising the steps consisting of i) determining the expression level of PLCyl in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing the stage of the patient according to the expression level of PLCyl .
In this case, according to the expression level of PLCyl, the patient suffering from a
CLL can be classified in CLL Binet Stage A (indolent CLL) or in CLL Binet Stages B/C (advanced disease, see for review Binet JL et al, 1981).
A patient with a CLL may be classified according to the Binet classification Nomenclature and criteria about this classification can be find in the National Cancer Institute website (http://www.cancer.gov/cancertopics/pdq/treatment/CLL/HealthProfessional/page2).
Typically, the sample according to the invention may be a blood, plasma, serum sample. In a particular embodiment, said sample is blood. The term "detecting" as used above includes qualitative and/or quantitative detection
(measuring levels) with or without reference to a control. Typically PLCyl expression may be measured for example by immunoblotting, enzyme-labeled and mediated immunoassays (such as ELISA), flow cytometry assessment or qRT-PCR performed on the sample. In these case, PLCyl mRNA or PLCyl protein can be detected.
Particularly, the methods of the invention further comprise a step of comparing the PLCyl expression level obtained in step a) to a threshold value.
The "control" may be a healthy subject, i.e. a subject who does not suffer from any cancer. Particularly, said control is a healthy subject.
Detection of PLCyl expression in the sample may be performed by measuring the level of PLCyl protein. In the present application, the "level of PLCyl protein" means the quantity or concentration of said PLCyl protein.
Such methods comprise contacting a sample with a binding partner capable of selectively interacting with PLCyl protein present in the sample. The binding partner is generally an antibody that may be polyclonal or monoclonal, particularly monoclonal.
The presence of the protein can be detected using standard electrophoretic and immunodiagnostic techniques, including immunoassays such as competition, direct reaction, or sandwich type assays. Such assays include, but are not limited to, Western blots; agglutination tests; enzyme-labeled and mediated immunoassays, such as ELISAs; biotin/avidin type assays; radioimmunoassays; Immunoelectrophoresis; immunoprecipitation, etc. The reactions generally include revealing labels such as fluorescent, chemiluminescent, radioactive, enzymatic labels or dye molecules, or other methods for detecting the formation of a complex between the antigen and the antibody or antibodies reacted therewith.
The aforementioned assays generally involve separation of unbound protein in a liquid phase from a solid phase support to which antigen-antibody complexes are bound. Solid supports which can be used in the practice of the invention include substrates such as nitrocellulose (e. g., in membrane or microtiter well form); polyvinylchloride (e. g., sheets or microtiter wells); polystyrene latex (e.g., beads or microtiter plates); polyvinylidine fluoride; diazotized paper; nylon membranes; activated beads, magnetically responsive beads, and the like.
More particularly, an ELISA method can be used, wherein the wells of a microtiter plate are coated with a set of antibodies against the proteins to be tested. A sample containing or suspected of containing the marker protein is then added to the coated wells. After a period of incubation sufficient to allow the formation of antibody-antigen complexes, the plate(s) can be washed to remove unbound moieties and a detectably labeled secondary binding molecule is added. The secondary binding molecule is allowed to react with any captured sample marker protein, the plate is washed and the presence of the secondary binding molecule is detected using methods well known in the art.
Various immunoenzymatic staining methods are known in the art for detecting a protein of interest. For example, immunoenzymatic interactions can be visualized using different enzymes such as peroxidase, alkaline phosphatase, or different chromogens such as DAB, AEC, or Fast Red; or fluorescent labels such as FITC, Cy3, Cy5, Cy7, Alexafluors, etc. Counterstains may include H&E, DAPI, Hoechst, so long as such stains are compatable with
other detection reagents and the visualization strategy used. As known in the art, amplification reagents may be used to intensify staining signal. For example, tyramide reagents may be used. The staining methods of the present invention may be accomplished using any suitable method or system as would be apparent to one of skill in the art, including automated, semi-automated or manual systems.
The method of the invention may comprise a further step consisting of comparing PLCyl expression with a control reference.
As used herein, "expression level of PLCyl " could also refer to an amount or a concentration of a transcription product, for instance mRNA coding for PLCyl , or of a translation product, for instance the protein PLCyl . Typically, a level of mRNA expression can be expressed in units such as transcripts per cell or nanograms per microgram of tissue. A level of protein can be expressed as nanograms per microgram of tissue or nanograms per milliliter of a culture medium, for example. Alternatively, relative units can be employed to describe an expression level.
In a one embodiment, when the measure of PLCyl protein is performed by quantitative RT-PCR (qPCR), immunob lotting or Flow cytometry the expression level of PLCyl protein in a patient suffering of a CLL Binet Stage A is increased by at least 100%, particularly by at least 1 10%; particularly by at least 120 %, particularly by at least 130%, particularly by at least 140%, more particularly by at least 150% compared to a control reference obtained in normal B cells. In other words, particularly, when PLCyl protein is measured, the quantity of PLCyl protein in a patient suffering of a CLL Binet Stage A is by at least 100%, particularly by at least 1 10%; particularly by at least 120 %, particularly by at least 130%, particularly by at least 140%, more particularly by at least 150% increased compared to a control reference obtained in normal B cells.
In another embodiment, when the measure of PLCyl protein is performed by qPCR or Flow cytometry, the expression level of PLCyl protein in a patient suffering of a CLL Binet Stage B/C is increased by at least 350%, particularly by at least 360%>; particularly by at least 370%), particularly by at least 380%), particularly by at least 390%, more particularly by at least 400% compared to a control reference in normal B cells. In other words, particularly, when PLCyl protein is measured, the quantity of PLCyl protein in a patient suffering of a CLL Binet Stage B/C is by at least 350%, particularly by at least 360%; particularly by at least 370%), particularly by at least 380%), particularly by at least 390%), more particularly by at least 400% increased compared to a control reference obtained in normal B cells.
Typically, a "threshold value", "threshold level" or "cut-off value" can be determined experimentally, empirically, or theoretically. A threshold value can also be arbitrarily selected based upon the existing experimental and/or clinical conditions, as would be recognized by a person of ordinary skilled in the art. Particularly, the person skilled in the art may compare the expression levels of PLCyl obtained according to the method of the invention with a defined threshold value.
Particularly, said threshold value is the mean expression level of PLCyl of a population of healthy individuals. As used herein, the term "healthy individual" denotes a human which is known to be healthy, i.e. which does not suffer from a cancer and in particular from a CLL and does not need any medical care.
Typically, the skilled person in the art may determine the expression level of PLCyl in a biological sample, particularly blood, of 100 individuals known to be healthy. The mean value of the obtained expression levels is then determined, according to well known statistical analysis, so as to obtain the mean expression level of PLCyl . Said value is then considered as being normal and thus constitutes a threshold value. By comparing the expression levels of PLCyl to this threshold value, the physician is then able to classify and prognostic the cancer. Indeed, by comparing the expression level of PLCyl obtained in a biological sample, particularly blood, of a given subject to a threshold value, one can easily determines the cancer stage of the subject or its prognostic.
Accordingly, the physician would be able to adapt and optimize appropriate medical care of a subject in a critical and life-threatening condition suffering from cancer. The determination of said prognosis is highly appropriate for follow-up care and clinical decision making.
Therefore, the invention is drawn to an in vitro method for classifying a patient suffering from cancer comprising the following steps:
a) determining the level of expression of PLCyl in a sample obtained from said patient; b) determining the mean expression level of PLCyl in a biological sample of a population of healthy individuals, particularly 100 healthy individuals; and
c) a step of comparing the expression level of PLCyl obtained of a) to the mean expression level of PLCyl obtained in b).
The present invention also relates to kits useful for the methods of the invention, comprising means for detecting PLCyl expression.
According to the invention, the kits of the invention may comprise an anti-PLCyl protein antibody; and another molecule coupled with a signalling system which binds to said PLCyl protein antibody.
Typically, the antibodies or combination of antibodies are in the form of solutions ready for use. In one embodiment, the kit comprises containers with the solutions ready for use. Any other forms are encompassed by the present invention and the man skilled in the art can routinely adapt the form to the use in immunohistochemistry.
In another embodiment, the invention relates to an in vitro method for monitoring a patient's response cancer treatment which comprises a step of measuring the level of PLCyl protein, in a sample from a patient.
Thus, the present invention relates to the use of PLCyl protein as a biomarker for the monitoring of anti cancer therapies.
According to the invention, the expression level of PLCyl protein may be determined to monitor a patient's response to cancer treatment and especially to monitor a patient's response to a CLL treatment. In another embodiment, the expression of PLCyl is a biomarker of cancer severity and especially in CLL severity.
In still another embodiment, the expression of PLCyl mRNA is a biomarker of cancer severity and especially in CLL severity. In another embodiment, the measurement of the expression level of the PLCyl protein may be used as a therapeutic companion test.
Therapeutic methods of patient with high expression level ofPLCy A second aspect of the invention relates to an agonist of CD47 receptor for use in the treatment of patient suffering of a cancer with a high expression level of PLCy.
In another embodiment, the invention also relates to an agonist of CD47 receptor for use in the treatment of patient suffering of a cancer with a poor outcome prognosis according to the prognostic method of the invention. In a one embodiment, the cancer is selected form the group consisting of adrenal cortical cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain and central nervous system cancer, breast cancer, Castleman disease, cervical cancer, colorectal cancer, endometrial cancer, oesophagus cancer, gallbladder cancer, gastrointestinal carcinoid tumors, Hodgkin's disease, non-Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, laryngeal and hypopharyngeal cancer, liver cancer, lung cancer, mesothelioma, plasmacytoma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cavity and oropharyngeal cancer, ovarian cancer, pancreatic cancer, penile cancer, pituitary cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, vaginal cancer, vulvar cancer, and uterine cancer.
In another particular embodiment, cancer is selected fro me thr group consisting of leukemia, acute lymphoblastic leukemia, B-chronic lymphocytic leukemia, hairy-cell leukemia, adult T-cell leukemia, prolymophocytic leukaemia of T-cell type or myeloid leukaemia.
In one embodiment, the leukemia is a B-chronic lymphocytic leukemia (CLL).
In a particular embodiment, the CLL is a refractory CLL (high-risk patients).
In one embodiment, the invention relates to an agonist of CD47 receptor for use in the treatment of CLL's patient with a high expression level of PLCy.
In another embodiment, the invention also relates to an agonist of CD47 receptor for use in the treatment of CLL's patient classified in CLL Binet Stage A or in CLL Binet Stages B/C).
To determine the expression level of PLCy or the stage of the patient, means as explained above in the invention may be used.
Typically, the agonist according to the invention includes but is not limited to a small organic molecule, an antibody, and a peptide/polypeptide.
In one embodiment, the agonist according to the invention is a soluble peptide comprising the amino acids sequence: KRFYVVMWK (SEQ ID NO: l) or a function- conservative variant thereof for use in the treatment of cancer.
The agonist also encompasses peptides that are function-conservative variants of the soluble peptide comprising SEQ ID NO: 1 as described here above.
In one embodiment, the soluble peptide according to the invention may differ from 1 , 2 or 3 amino acids to the SEQ ID NO: 1.
In another embodiment, the soluble peptide according to the invention may differ from 4 or 5 amino acids to the SEQ ID NO : 1.
In one embodiment, the soluble peptide of the invention comprises at least 75% identity over said the SEQ ID NO: 1, even more particularly at least 80%, at least 85%, at least 90%), at least 95%, at least 97% and is still able to decrease tumor cell proliferation or still able to induce PCD in tumor cell.
In one embodiment, the soluble peptide of the invention consists in the amino acid sequence as set forth in SEQ ID NO:l or a variant thereof comprising at least 75%, particularly at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identity with SEQ ID NO: l and is still able to decrease tumor cell proliferation or still able to induce PCD in tumor cells.
To verify whether the newly generated soluble peptides induce the same type of caspase-independent PCD than the initially characterized peptide 4N1K a flow cytometry analysis may be performed with each peptide. A comparison of the results obtained in treatments with/without the caspase inhibitor Z-VAD.fmk will corroborate that the mode of cell death induced by the 4NlK-derived peptides is caspase-independent. Additionally, a time-course and a dose-response performed in different tumor cells will determine the optimal conditions for each peptide and each malignant cell type.
In one embodiment of the invention, said soluble peptide is an amino acid sequence of less than 50 amino acids long that comprises the amino acid sequence SEQ ID NO: l as defined here above.
In another embodiment of the invention, said soluble peptide is an amino acid sequence of less than 45 amino acids long that comprises the amino acid sequence SEQ ID NO: l as defined here above.
In another embodiment of the invention, said soluble peptide is an amino acid sequence of less than 40 amino acids long that comprises the amino acid sequence SEQ ID NO: l as defined here above.
In another embodiment of the invention, said soluble peptide is an amino acid sequence of less than 30 amino acids long that comprises the amino acid sequence SEQ ID NO: l as defined here above.
In another embodiment of the invention, said soluble peptide is an amino acid sequence of less than 20 amino acids long that comprises the amino acid sequence SEQ ID NO: l as defined here above.
In another embodiment of the invention, said soluble peptide is an amino acid sequence of less than 15 amino acids long that comprises the amino acid sequence SEQ ID NO: l as defined here above.
As used herein, the term "Function-conservative variants" refer to those in which a given amino acid residue in a protein or enzyme has been changed (inserted, deleted or substituted) without altering the overall conformation and function of the peptide. Such variants include protein having amino acid alterations such as deletions, insertions and/or substitutions. A "deletion" refers to the absence of one or more amino acids in the protein. An "insertion" refers to the addition of one or more of amino acids in the protein. A "substitution" refers to the replacement of one or more amino acids by another amino acid residue in the protein. Typically, a given amino acid is replaced by an amino acid having similar properties (such as, for example, polarity, hydrogen bonding potential, acidic, basic, hydrophobic, aromatic, and the like). This given amino acid can be a natural amino acid or a non natural amino acid. Amino acids other than those indicated as conserved may differ in a protein so that the percent protein or amino acid sequence similarity between any two proteins of similar function may vary and may be, for example, from 70 % to 99 % as determined according to an alignment scheme such as by the Cluster Method, wherein similarity is based on the MEGALIGN algorithm. A "function-conservative variant" also includes a polypeptide which has at least 60 % amino acid identity as determined by BLAST or FASTA algorithms, particularly at least 75 %, more particularly at least 85%, still particularly at least 90 %, and even more particularly at least 95%, and which has the same or substantially similar properties or functions as the native or parent protein to which it is compared. Two amino acid sequences are "substantially homologous" or "substantially similar" when greater than 80 %, particularly greater than 85 %, particularly greater than 90 % of the amino acids are
identical, or greater than about 90 %, particularly greater than 95 %, are similar (functionally identical) over the whole length of the shorter sequence. Particularly, the similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wisconsin) pileup program, or any of sequence comparison algorithms such as BLAST, FASTA, etc.
Typically, the invention encompasses soluble peptides substantially identical to the soluble peptide comprising SEQ ID NO:l in which one or more residues have been conservatively substituted with a functionally similar residue and which displays the functional aspects of the soluble peptides comprising SEQ ID NO: l as described here above, i.e. being still able to decrease tumor cell proliferation in substantially the same way as a peptide consisting of the given amino acid sequence.
Examples of conservative substitutions include the substitution of one non-polar (hydrophobic) residue such as iso leucine, valine, leucine or methionine for another, the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine, the substitution of one basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue, such as aspartic acid or glutamic acid or another.
The term "conservative substitution" also includes the use of a chemically derivatized residue in place of a non-derivatized residue. "Chemical derivative" refers to a subject peptide having one or more residues chemically derivatized by reaction of a functional side group. Examples of such derivatized molecules include for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine may be derivatized to form N-im- benzylhistidine. Chemical derivatives also include peptides that contain one or more naturally-occurring amino acid derivatives of the twenty standard amino acids. For examples: 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine. The term "conservative substitution" also includes the use of non natural amino acids aimed to control and stabilize peptides or proteins secondary structures. These non natural amino acids are chemically modified amino acids
such as prolinoamino acids, beta-amino acids, N-methylamino acids, cyclopropylamino acids, alpha,alpha-substituted amino acids as describe here below. These non natural amino acids may include also fluorinated, chlorinated, brominated- or iodinated modified amino acids. In one embodiment, soluble peptides of the invention may be as described in example
3.
In another embodiment, the soluble peptide of the invention is the PKHB1 peptide as describe in example 3.
In another embodiment, the soluble peptide of the invention is the PKHB3 peptide as describe in example 3.
In another embodiment, the soluble peptide of the invention is the PKHB4 peptide as describe in example 3.
In another embodiment, the soluble peptide of the invention is the PKHB9 peptide as describe in example 3.
In another embodiment, the soluble peptide of the invention is the PKHB10 peptide as describe in example 3.
In another embodiment, the soluble peptide of the invention is the PKHB11 peptide as describe in example 3. In one embodiment, soluble peptides of the invention may comprise a tag. A tag is an epitope-containing sequence which can be useful for the purification of the soluble peptides. It is attached to by a variety of techniques such as affinity chromatography, for the localization of said peptide or polypeptide within a cell or a tissue sample using immuno labeling techniques, the detection of said peptide or polypeptide by immunob lotting etc. Examples of tags commonly employed in the art are the GST (glutathion-S-transferase)- tag, the FLAG™-tag, the Strep-tag™, V5 tag, myc tag, His tag etc.
In one embodiment, soluble peptides of the invention may be labelled by a fluorescent dye. Dye-labelled fluorescent peptides are important tools in cellular studies. Peptides can be labelled on the N-terminal side or on the C-terminal side.
N-Terminal Peptide Labeling Using Amine-Reactive Fluorescent Dyes:
Amine-reactive fluorescent probes are widely used to modify peptides at the N- terminal or lysine residue. A number of fluorescent amino -reactive dyes have been developed
to label various peptides, and the resultant conjugates are widely used in biological applications. Three major classes of amine-reactive fluorescent reagents are currently used to label peptides: succinimidyl esters (SE), isothiocyanates and sulfonyl chlorides.
C-Terminal Labeling Using Amine-Containing Fluorescent Dyes:
Amine-containing dyes are used to modify peptides using water-soluble carbodiimides (such as EDC) to convert the carboxy groups of the peptides into amide groups. Either NHS or NHSS may be used to improve the coupling efficiency of EDC-mediated protein- carboxylic acid conjugations.
Labelled peptides derived from 4N1K have the following general formula:
Where X and/or Y can be nothing or hydrogen and/or spacers and/or fluorescent dyes.
PKHB8 (formula (VII)) is an example of peptide from this series where a spacer formed by two beta-alanine residues and a fluorescent dye (fluorescein) have been introduced on the N-terminal side of the eptide, on the alpha-amino group of the lysine residue:
Formula (VII)
In another embodiment, the soluble peptide of the invention is the PKHB8 peptide.
In specific embodiments, it is contemplated that soluble peptides used in the therapeutic methods of the present invention may be modified in order to improve their therapeutic efficacy. Such modification of therapeutic compounds may be used to decrease toxicity, increase circulatory time, or modify biodistribution. For example, the toxicity of potentially important therapeutic compounds can be decreased significantly by combination with a variety of drug carrier vehicles that modify biodistribution.
A strategy for improving drug viability is the utilization of water-soluble polymers. Various water-soluble polymers have been shown to modify biodistribution, improve the mode of cellular uptake, change the permeability through physiological barriers; and modify the rate of clearance from the body. To achieve either a targeting or sustained-release effect, water-soluble polymers have been synthesized that contain drug moieties as terminal groups, as part of the backbone, or as pendent groups on the polymer chain.
Polyethylene glycol (PEG) has been widely used as a drug carrier, given its high degree of biocompatibility and ease of modification. Attachment to various drugs, proteins, and liposomes has been shown to improve residence time and decrease toxicity. PEG can be coupled to active agents through the hydroxyl groups at the ends of the chain and via other chemical methods; however, PEG itself is limited to at most two active agents per molecule. In a different approach, copolymers of PEG and amino acids were explored as novel bio materials which would retain the biocompatibility properties of PEG, but which would have the added advantage of numerous attachment points per molecule (providing greater drug loading), and which could be synthetically designed to suit a variety of applications.
Those of skill in the art are aware of PEGylation techniques for the effective modification of drugs. For example, drug delivery polymers that consist of alternating polymers of PEG and tri- functional monomers such as lysine have been used by VectraMed (Plainsboro, N.J.). The PEG chains (typically 2000 daltons or less) are linked to the a- and e- amino groups of lysine through stable urethane linkages. Such copolymers retain the desirable properties of PEG, while providing reactive pendent groups (the carboxylic acid groups of lysine) at strictly controlled and predetermined intervals along the polymer chain. The reactive pendent groups can be used for derivatization, cross-linking, or conjugation with other molecules. These polymers are useful in producing stable, long-circulating pro-drugs by varying the molecular weight of the polymer, the molecular weight of the PEG segments, and the cleavable linkage between the drug and the polymer. The molecular weight of the PEG segments affects the spacing of the drug/linking group complex and the amount of drug per molecular weight of conjugate (smaller PEG segments provides greater drug loading). In
general, increasing the overall molecular weight of the block co-polymer conjugate will increase the circulatory half-life of the conjugate. Nevertheless, the conjugate must either be readily degradable or have a molecular weight below the threshold- limiting glomular filtration (e.g., less than 45 kDa).
In addition, to the polymer backbone being important in maintaining circulatory half- life, and biodistribution, linkers may be used to maintain the therapeutic agent in a pro-drug form until released from the backbone polymer by a specific trigger, typically enzyme activity in the targeted tissue. For example, this type of tissue activated drug delivery is particularly useful where delivery to a specific site of biodistribution is required and the therapeutic agent is released at or near the site of pathology. Linking group libraries for use in activated drug delivery are known to those of skill in the art and may be based on enzyme kinetics, prevalence of active enzyme, and cleavage specificity of the selected disease-specific enzymes (see e.g., technologies of established by VectraMed, Plainsboro, N.J.). Such linkers may be used in modifying the soluble peptides-derived described herein for therapeutic delivery.
According to the invention, soluble peptides may be produced by conventional automated peptide synthesis methods or by recombinant expression. General principles for designing and making proteins are well known to those of skill in the art.
Soluble peptides of the invention may be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols as described in Stewart and Young; Tarn et al, 1983; Merrifield, 1986 and Barany and Merrifield, Gross and Meienhofer, 1979. Soluble peptides of the invention may also be synthesized by solid-phase technology employing an exemplary peptide synthesizer such as a Model 433 A from Applied Biosystems Inc. The purity of any given protein; generated through automated peptide synthesis or through recombinant methods may be determined using reverse phase HPLC analysis. Chemical authenticity of each peptide may be established by any method well known to those of skill in the art.
As an alternative to automated peptide synthesis, recombinant DNA technology may be employed wherein a nucleotide sequence which encodes a protein of choice is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression as described herein below. Recombinant methods are especially preferred for producing longer polypeptides.
A variety of expression vector/host systems may be utilized to contain and express the peptide or protein coding sequence. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors (Giga-Hama et al, 1999); insect cell systems infected with virus expression vectors (e.g., baculovirus, see Ghosh et al, 2002); plant cell systems transfected with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with bacterial expression vectors (e.g., Ti or pBR322 plasmid; see e.g., Babe et al, 2000); or animal cell systems. Those of skill in the art are aware of various techniques for optimizing mammalian expression of proteins, see e.g., Kaufman, 2000; Colosimo et al, 2000. Mammalian cells that are useful in recombinant protein productions include but are not limited to VERO cells, HeLa cells, Chinese hamster ovary (CHO) cell lines, COS cells (such as COS-7), W138, BHK, HepG2, 3T3, RIN, MDCK, A549, PC12, K562 and 293 cells. Exemplary protocols for the recombinant expression of the peptide substrates or fusion polypeptides in bacteria, yeast and other invertebrates are known to those of skill in the art and a briefly described herein below. U.S. Pat. No. 6,569,645; U.S. Pat. No. 6,043,344; U.S. Pat. No. 6,074,849; and U.S. Pat. No. 6,579,520 provide specific examples for the recombinant production of soluble peptides and these patents are expressly incorporated herein by reference for those teachings. Mammalian host systems for the expression of recombinant proteins also are well known to those of skill in the art. Host cell strains may be chosen for a particular ability to process the expressed protein or produce certain post-translation modifications that will be useful in providing protein activity. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be important for correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, 293, WI38, and the like have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the introduced, foreign protein.
In the recombinant production of the soluble peptides-derived of the invention, it would be necessary to employ vectors comprising polynucleotide molecules for encoding the soluble peptides-derived. Methods of preparing such vectors as well as producing host cells transformed with such vectors are well known to those skilled in the art. The polynucleotide molecules used in such an endeavor may be joined to a vector, which generally includes a selectable marker and an origin of replication, for propagation in a host. These elements of the
expression constructs are well known to those of skill in the art. Generally, the expression vectors include DNA encoding the given protein being operably linked to suitable transcriptional or translational regulatory sequences, such as those derived from a mammalian, microbial, viral, or insect genes. Examples of regulatory sequences include transcriptional promoters, operators, or enhancers, mRNA ribosomal binding sites, and appropriate sequences which control transcription and translation.
The terms "expression vector," "expression construct" or "expression cassette" are used interchangeably throughout this specification and are meant to include any type of genetic construct containing a nucleic acid coding for a gene product in which part or all of the nucleic acid encoding sequence is capable of being transcribed.
The choice of a suitable expression vector for expression of the peptides or polypeptides of the invention will of course depend upon the specific host cell to be used, and is within the skill of the ordinary artisan. Methods for the construction of mammalian expression vectors are disclosed, for example, in Okayama and Berg, 1983; Cosman et al, 1986; Cosman et al, 1984; EP-A-0367566; and WO 91/18982. Other considerations for producing expression vectors are detailed in e.g., Makrides et al, 1999; Kost et al, 1999. Wurm et al., 1999 is incorporated herein as teaching factors for consideration in the large- scale transient expression in mammalian cells for recombinant protein production.
Expression requires that appropriate signals be provided in the vectors, such as enhancers/promoters from both viral and mammalian sources that may be used to drive expression of the nucleic acids of interest in host cells. Usually, the nucleic acid being expressed is under transcriptional control of a promoter. A "promoter" refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene. Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the DNA encoding the peptide of interest (i.e., 4N1K, a variant and the like). Thus, a promoter nucleotide sequence is operably linked to a given DNA sequence if the promoter nucleotide sequence directs the transcription of the sequence.
Similarly, the phrase "under transcriptional control" means that the promoter is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the gene. Any promoter that will drive the expression of the nucleic acid may be used. The particular promoter employed to control the expression of a nucleic acid sequence of interest is not believed to be important, so long as it is capable of directing the expression of the nucleic acid in the targeted cell. Thus, where a human cell is
targeted, it is preferable to position the nucleic acid coding region adjacent to and under the control of a promoter that is capable of being expressed in a human cell. Generally speaking, such a promoter might include either a human or viral promoter. Common promoters include, e.g., the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter, the Rous sarcoma virus long terminal repeat, [beta]-actin, rat insulin promoter, the phosphoglycerol kinase promoter and glyceraldehyde-3 -phosphate dehydrogenase promoter, all of which are promoters well known and readily available to those of skill in the art, can be used to obtain high-level expression of the coding sequence of interest. The use of other viral or mammalian cellular or bacterial phage promoters which are well-known in the art to achieve expression of a coding sequence of interest is contemplated as well, provided that the levels of expression are sufficient to produce a recoverable yield of protein of interest. By employing a promoter with well known properties, the level and pattern of expression of the protein of interest following transfection or transformation can be optimized. Inducible promoters also may be used.
Another regulatory element that is used in protein expression is an enhancer. These are genetic elements that increase transcription from a promoter located at a distant position on the same molecule of DNA. Where an expression construct employs a cDNA insert, one will typically desire to include a polyadenylation signal sequence to effect proper polyadenylation of the gene transcript. Any polyadenylation signal sequence recognized by cells of the selected transgenic animal species is suitable for the practice of the invention, such as human or bovine growth hormone and SV40 polyadenylation signals.
Acids nucleic, Vectors, recombinant host cells and uses thereof
A third object of the invention relates to a nucleic acid encoding an amino acids sequence comprising SEQ ID NO: 1 or a function-conservative variant thereof as described here above for use in the treatment of patient suffering of a cancer with a high expression level of PLCy.
In one embodiment, the invention also relates to a nucleic acid encoding an amino acids sequence comprising SEQ ID NO: 1 or a function-conservative variant thereof as described here above for use in the treatment of patient suffering of a cancer with a poor outcome prognosis according to the prognostic method of the invention.
In a one embodiment, the cancer is selected form the group consisting of adrenal cortical cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain and central nervous system cancer, breast cancer, Castleman disease, cervical cancer, colorectal cancer, endometrial cancer, oesophagus cancer, gallbladder cancer, gastrointestinal carcinoid tumors, Hodgkin's disease, non-Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, laryngeal and hypopharyngeal cancer, liver cancer, lung cancer, mesothelioma, plasmacytoma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cavity and oropharyngeal cancer, ovarian cancer, pancreatic cancer, penile cancer, pituitary cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, vaginal cancer, vulvar cancer, and uterine cancer.
In another particular embodiment, cancer is selected fro me thr group consisting of leukemia, acute lymphoblastic leukemia, B-chronic lymphocytic leukemia, hairy-cell leukemia, adult T-cell leukemia, prolymophocytic leukaemia of T-cell type or myeloid leukaemia.
In one embodiment, the leukemia is a B-chronic lymphocytic leukemia (CLL).
In a particular embodiment, the CLL is a refractory CLL. In one embodiment, the invention relates to a nucleic acid encoding an amino acids sequence comprising SEQ ID NO: 1 or a function-conservative variant thereof as described here above for use in the treatment of CLL's patient with a high expression level of PLCy.
In another embodiment, the invention relates to a nucleic acid encoding an amino acids sequence comprising SEQ ID NO: 1 or a function-conservative variant thereof as described here above for use in the treatment of CLL's patient classified in CLL Binet Stage A or in CLL Binet Stages B/C).
In one embodiment, said nucleic acid encoding an amino acids sequence consisting on SEQ ID NO: 1.
Nucleic acids of the invention may be produced by any technique known per se in the art, such as, without limitation, any chemical, biological, genetic or enzymatic technique, either alone or in combination(s).
Another object of the invention is an expression vector comprising a nucleic acid sequence encoding an amino sequence comprising SEQ ID NO: 1 or a function-conservative variant thereof as described here above for use in the prevention or treatment of cancer. According to the invention, expression vectors suitable for use in the invention may comprise at least one expression control element operationally linked to the nucleic acid sequence. The expression control elements are inserted in the vector to control and regulate the expression of the nucleic acid sequence. Examples of expression control elements include, but are not limited to, lac system, operator and promoter regions of phage lambda, yeast promoters and promoters derived from polyoma, adenovirus, retrovirus, lentivirus or SV40. Additional preferred or required operational elements include, but are not limited to, leader sequence, termination codons, polyadenylation signals and any other sequences necessary or preferred for the appropriate transcription and subsequent translation of the nucleic acid sequence in the host system. It will be understood by one skilled in the art that the correct combination of required or preferred expression control elements will depend on the host system chosen. It will further be understood that the expression vector should contain additional elements necessary for the transfer and subsequent replication of the expression vector containing the nucleic acid sequence in the host system. Examples of such elements include, but are not limited to, origins of replication and selectable markers. It will further be understood by one skilled in the art that such vectors are easily constructed using conventional methods or commercially available.
Another object of the invention is a host cell comprising an expression vector as described here above for use in the prevention or treatment of cancer.
According to the invention, examples of host cells that may be used are eukaryote cells, such as animal, plant, insect and yeast cells and prokaryotes cells, such as E. coli. The means by which the vector carrying the gene may be introduced into the cells include, but are not limited to, microinjection, electroporation, transduction, or transfection using DEAE- dextran, lipofection, calcium phosphate or other procedures known to one skilled in the art.
In another embodiment, eukaryotic expression vectors that function in eukaryotic cells are used. Examples of such vectors include, but are not limited to, viral vectors such as retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, poxvirus, poliovirus; lentivirus, bacterial expression vectors, plasmids, such as pcDNA3 or the baculovirus transfer vectors. Preferred eukaryotic cell lines include, but are not limited to,
COS cells, CHO cells, HeLa cells, NIH/3T3 cells, 293 cells (ATCC# CRL1573), T2 cells, dendritic cells, or monocytes.
Therapeutic methods
A fourth aspect of the invention relates to a compound which active the PLCyl for use in the treatment of cancer. As used herein, the term "active PLCyl" denotes the activation of the PLCyl by the phosphorylation of PLCyl in the tyrosine 783 (Y783). Once activated, PLCyl-Y783 catalyzes the formation of inositol 1,4,5-triphosphate (IP3), which, in turn, generates the endoplasmic reticulum-mediated Ca2+ deregulation that provokes caspase-independent PCD. In a one embodiment, the cancer is selected form the group consisting of adrenal cortical cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain and central nervous system cancer, breast cancer, Castleman disease, cervical cancer, colorectal cancer, endometrial cancer, oesophagus cancer, gallbladder cancer, gastrointestinal carcinoid tumors, Hodgkin's disease, non-Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, laryngeal and hypopharyngeal cancer, liver cancer, lung cancer, mesothelioma, plasmacytoma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cavity and oropharyngeal cancer, ovarian cancer, pancreatic cancer, penile cancer, pituitary cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, vaginal cancer, vulvar cancer, and uterine cancer.
In another particular embodiment, cancer is selected from the group consisting of leukemia, acute lymphoblastic leukemia, B-chronic lymphocytic leukemia, hairy-cell leukemia, adult T-cell leukemia, prolymophocytic leukaemia of T-cell type or myeloid leukaemia.
In one embodiment, the leukemia is a B-chronic lymphocytic leukemia (CLL).
In a particular embodiment, the CLL is a refractory CLL.
Typically, the compound according to the invention includes but is not limited to a small organic molecule, an antibody, and a polypeptide.
In one embodiment, the compound according to the invention may be a low molecular weight compound, e. g. a small organic molecule (natural or not).
The term "small organic molecule" refers to a molecule (natural or not) of a size comparable to those organic molecules generally used in pharmaceuticals. The term excludes biological macromolecules (e. g., proteins, nucleic acids, etc.). Preferred small organic molecules range in size up to about 10000 Da, more particularly up to 5000 Da, more particularly up to 2000 Da and most particularly up to about 1000 Da. In one embodiment, the compound according to the invention may be a kinase, which will activate the PLCyl that is to say which will phosphorylate the PLCyl in the tyrosine 783 (Y783). Kinases of the invention can be SRC (LCK, FynT, LYN), SYK (SYK, ZAP70), and TEC (ITK, RLK, TEC, BTK) kinases (for review see: Wilde JI et al, 2011). In another embodiment, the compound according to the invention may be an inhibitor of a phosphatase which will deactivate the PLCyl that is to say which will dephosphorylate the PLCyl in the tyrosine 783 (Y783). Phosphatases of the invention can be PTP1B, PTPRM (see for review: Phillips-Mason PJ et al, 2011). Thus, in another embodiment, the invention relates to a compound which active the
PLCyl by phosphorylation of the tyrosine 783 (Y783) for use in the treatment of cancer.
In one embodiment, the compound according to the invention is an antibody linked to a kinase which activate the PLCyl that is to say which will phosphorylate the PLCyl in the tyrosine 783 (Y783) may be used. Accordingly, the antibody will be directed against PLCyl .
Antibody against PLCyl can be raised according to known methods by administering the appropriate antigen or epitope to a host animal selected, e.g., from pigs, cows, horses, rabbits, goats, sheep, and mice, among others. Various adjuvants known in the art can be used to enhance antibody production. Although antibodies useful in practicing the invention can be polyclonal, monoclonal antibodies are preferred. Monoclonal antibodies against PLCyl can be prepared and isolated using any technique that provides for the production of antibody molecules by continuous cell lines in culture. Techniques for production and isolation include but are not limited to the hybridoma technique originally described by Kohler and Milstein (1975); the human B-cell hybridoma technique (Cote et al., 1983); and the EBV-hybridoma
technique (Cole et al. 1985). Alternatively, techniques described for the production of single chain antibodies (see e.g., U.S. Pat. No. 4,946,778) can be adapted to produce anti-PLCyl single chain antibodies. Coumpounds useful in practicing the present invention also include anti- PLCyl antibody fragments including but not limited to F(ab')2 fragments, which can be generated by pepsin digestion of an intact antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab and/or scFv expression libraries can be constructed to allow rapid identification of fragments having the desired specificity to PLCyl .
Humanized anti-PLCyl antibodies and antibody fragments thereof can also be prepared according to known techniques. "Humanized antibodies" are forms of non-human (e.g., rodent) chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region (CDRs) of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity and capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Methods for making humanized antibodies are described, for example, by Winter (U.S. Pat. No. 5,225,539) and Boss (Celltech, U.S. Pat. No. 4,816,397).
In another embodiment, the compound according to the invention is an antibody linked to an inhibitor of a phosphatase which will deactivate the PLCyl that is to say which will dephosphorylate the PLCyl in the tyrosine 783 (Y783). Accordingly, the antibody will be directed against PLCyl or against the phosphatase.
Another object of the invention relates to a method for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound which active the PLCyl .
In one embodiment, said compound is a kinase.
In another embodiment, the cancer is a CLL.
In another embodiment, the CLL is a refractory CLL. The invention relates to a method for treating patient who has been considered as a poor outcome prognosis for the survival time of a cancer according to the invention comprising administering to a subject in need thereof a compound which active the PLCyl .
In another embodiment, the compound of the invention may be a peptide or a polypeptide derived from the PLCy comprising the tyrosine 783 (Y783) phosphorylated for use in the treatment of cancer.
The peptide or the polypeptide derived from the PLCy comprising the tyrosine 783 (Y783) phosphorylated is able to treat cancer through its properties of decoy receptor.
By "decoy receptor", is meant that the peptides or the polypeptides according to the invention mime the phosphorylated PLCy and is dephosphorylated instead of the PLCy.
Therapeutic composition A fifth aspect of the invention relates to a therapeutic composition comprising a compound which active the PLCyl for use in the treatment of cancer.
In another embodiment, the invention relates to a therapeutic composition comprising an agonist as described above for use in the treatment of cancer.
In a one embodiment, the cancer is selected form the group consisting of adrenal cortical cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain and central nervous system cancer, breast cancer, Castleman disease, cervical cancer, colorectal cancer, endometrial cancer, oesophagus cancer, gallbladder cancer, gastrointestinal carcinoid tumors, Hodgkin's disease, non-Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, laryngeal and hypopharyngeal cancer, liver cancer, lung cancer, mesothelioma, plasmacytoma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cavity and oropharyngeal cancer, ovarian cancer, pancreatic cancer, penile cancer, pituitary cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer,
stomach cancer, testicular cancer, thymus cancer, thyroid cancer, vaginal cancer, vulvar cancer, and uterine cancer.
In another particular embodiment, cancer is selected fro me thr group consisting of leukemia, acute lymphoblastic leukemia, B-chronic lymphocytic leukemia, hairy-cell leukemia, adult T-cell leukemia, prolymophocytic leukaemia of T-cell type or myeloid leukaemia.
In one embodiment, the leukemia is a B-chronic lymphocytic leukemia (CLL).
In a particular embodiment, the CLL is a refractory CLL. Any therapeutic agent of the invention may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form therapeutic compositions.
"Pharmaceutically" or "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate. A pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
The form of the pharmaceutical compositions, the route of administration, the dosage and the regimen naturally depend upon the condition to be treated, the severity of the illness, the age, weight, and sex of the patient, etc.
The pharmaceutical compositions of the invention can be formulated for a topical, oral, intranasal, parenteral, intraocular, intravenous, intramuscular or subcutaneous administration and the like.
Particularly, the pharmaceutical compositions contain vehicles, which are pharmaceutically acceptable for a formulation capable of being injected. These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.
The doses used for the administration can be adapted as a function of various parameters, and in particular as a function of the mode of administration used, of the relevant pathology, or alternatively of the desired duration of treatment.
In addition, other pharmaceutically acceptable forms include, e.g. tablets or other solids for oral administration; time release capsules; and any other form currently can be used.
Pharmaceutical compositions of the present invention may comprise a further therapeutic active agent.
The present invention also relates to a kit comprising a compound according to the invention and further a therapeutic active agent.
The invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.
FIGURES:
Figure 1: PLCyl is over-expressed in CLL.
(A) PLCGl mRNA levels of normal B-cells (from healthy donors n=l l) and B- lymphocytes from CLL patients (n=50). The numbers refer to the mean PLCGl transcript expression. GUSB mRNA level was used to normalize the data. (B) The PLCGl mRNA expression level measured in the panel of B-lymphocytes used in (A) was represented by discriminating the CLL patients by their clinical Binet Stage. The numbers refer to the mean PLCGl transcript expression. (C) The PLCGl mRNA expression level measured in the panel of normal B-cells and in CLL B-lymphocytes used in (A) was represented by discriminating the CLL patients by their TP53 and ATM gene status (functional or dysfunctional). GUSB mRNA level was used to normalize the data. (D) The PLCGl mRNA expression level measured in the panel of normal B-cells and in CLL B-lymphocytes used in (A) was represented by discriminating the CLL patients by their ZAP70 levels.
Figure 2: PLCyl controls PKHBl-induced PCD.
(A) IP1 production was quantified in PKHB1 -treated normal and CLL B-cells. The histogram depicts the mean ± s.d. (n=7). (B) IP1 generation was determined in PKHB1- treated CLL B-lymphocytes pre-incubated with vehicle or the PLC inhibitor U73122. Data in the plot are the mean ± s.d. (n=5 patients). Immunoblotting confirmed that U73122 inhibited PLCyl -Y783 phosphorylation. Equal loading was confirmed by PLCyl probing. (C) Cell death was measured in untreated (Control) or PKHB1 -treated CLL cells incubated with vehicle or U73122. Data are presented as the mean ± s.d. (n=10). (D) The effects of down-
regulating PLCyl by shRNA on CD47-mediated PCD were assessed in leukemic B-cells transduced with scrambled shRNA (Scr) or two shRNAs targeting PLCyl (shRNA PLCylA and B). Data are presented as the mean ± s.d. (n=6). Changes in PLCyl expression were observed by immunoblotting. Equal loading was confirmed by a-tubulin detection.
Figure: 3. PKHBl reduced in vivo CLL tumor burden by inducing PLCyl activation.
PLCyl -Y783 phosphorylation was assessed in tumors obtained from the vehicle (Control) and PKHBl -treated mice. Phospho-PLCyl was quantified using flow cytometry by the mean fluorescence intensity. The data are presented as the mean ± s.d. (n= 6).
EXAMPLE:
Material & Methods
Patients, B-cell purification, and culture conditions.
CLL patients were diagnosed according to classical morphological and immunophenotypic criteria. This includes clinical Binet staging and the biological parameters IGVH mutational status, CD38, and ZAP-70 levels. Deletions of 17pl3, l lq22 andl3ql4 and trisomy 12 were detected by fluorescence in situ hybridization (FISH) using the Vysis LSI p53 / LSI ATM and LSI D13S319 / LSI 13q34 / CEP 12 Multi-color Probe kits (Abbott Molecular). The functional status of TP53 was determined by flow cytometry as previously published (Le Garff Tavernier et al. Functional assessment of p53 in chronic lymphocytic leukemia. Blood Cancer J. 2011 Feb;l(2):e5. doi: 10.1038 bcj .2011.3). TP53 mutations were detected using high resolution melting (HRM) and confirmed by sequencing the amplicons with an abnormal HRM profile. Mononuclear cells were purified and selected using magnetic microbeads (Miltenyi Biotec). B-lymphocytes, MEC-1 and M210B4 bone marrow stromal cells (ATCC) were cultured in complete medium (RPMI 1640 supplemented with 10% fetal calf serum, 2 mM L-glutamine and 100 U/ml penicillin- streptomycin). This CLL work was approved by the Institutional Ethics Committee at Pitie-Salpetriere Hospital.
Peptide synthesis.
Peptides were synthesized by SPPS on a preloaded Fmoc-Lys(Boc)-Wang or Fmoc-D- ioc)-Wang resins (Merck Chemicals). The syntheses were performed on an ABI 433 A
peptide synthesizer (Applied Biosystems) at the 0.25 mmol scale. Peptides were purified by reverse phase HPLC on an ACE (C8, 5 μηι, 300 A, 10 mm x 250 mm) column (Waters) with a gradient elution [0.1% (v/v) TFA in acetonitrile] in aqueous 0.1% (v/v) TFA. Homogeneous fractions were pooled and lyophilized after confirming a purity of greater than 95% by analytical HPLC.
PKHB1, 4N1K, and 4NGG: All Na-Fmoc-amino acids (10 equiv.) were coupled after activation with HBTU (0.45 M in NMP) in the presence of DIEA (6 equiv., 2 M in NMP) (10 equiv., 1 : 1). N-Fmoc deprotection was performed using piperidine (20%> in NMP) and was monitored by measuring the UV absorbance of the released N-(9-fluorenylmethyl)-piperidine group at 301 nm. PKHB1, MALDI-TOF MS (4N1K (SEQ ID NO: l) with first lysine amino acid in (D) form and last lysine amino acid in form (D)) (MH+) calculated: 1383.8, (MH+) actual: 1385.3. 4N IK, MALDI-TOF MS: K-R-F-Y-V-V-M-W-K-K (SEQ ID NO: 1) (MH+) calculated: 1383.8, (MH+) actual: 1385.0. 4NGG, MALDI-TOF MS: K-R-F-Y-G-G-M-W-K- K (SEQ ID NO: 2) (MH+) calculated: 1300.70, (MH+) actual: 1300.4.
Peptide degradation assays.
4N1K or PKHB1 (lOmg/mL), diluted in a mixture 1/4 human serum/RPMI 1640, were incubated at 37°C at different times. Then, mixed with ethanol and 5 ml of 1M NaOH and incubated at 4 °C for at least 15 min to precipitate serum proteins. The supernatant was collected, injected in an HPLC and the soluble peptide was eluted by a linear gradient 5 to 50% ACN [0.1% (v/v) TFA in acetonitrile] in aqueous 0.1% (v/v) TFA. The concentration of the peptide was calculated by the integration of the absorbance at 220 nm as a function of retention time. Flow cytometry.
Annexin V-APC (0.1 μ^ιηΐ) was used for the assessment of PS exposure, propidium iodide (PI, 0.5 μ^πύ) for PCD analysis, and tetramethylrhodamine ethyl ester (TMRE, 20 nM) for ΔΨιη quantification. PCD was recorded in a FACSCanto II (BD Biosciences) in the total population (10,000 cells) and data were analyzed using Flow Jo software. CD5+/CD5- discrimination was determined with anti-CD5-PE-Cy7 mAb (clone L17F12; BD Biosciences), calreticulin cell surface exposure was recorded with anti-calreticulin-PE (clone FMC75; Assay Designs), CD47 analysis was assessed with conjugated anti-CD47-PE (clone B6H12; BD Biosciences), p21 with anti-p21-FITC (clone EA10; Calbiochem), and p53 with
anti-p53-PE (clone DO-7; BD Biosciences). QuantiBrite flow cytometry System (BD Biosciences) was used to assess the number of CD47 molecules expressed on B-lymphocytes.
Cell death induction and inhibition.
To induce death, cells were treated for 2 h with PKHB1 (200 μΜ), 4N1K (300 μΜ), or 4NGG (300 μΜ). To control for caspase-dependent apoptosis, cells were incubated for 24 h with etoposide (250 μΜ). For the inhibition assays, BAPTA-AM (20 μΜ), BAPTA (5 mM), Ru360 (750 nM), dantrolene (40 μΜ), 2-minoethoxydiphenyl borate (2-APB, 60 μΜ), U73122 (200 nM), the broad spectrum caspase inhibitors Q-VD-OPh (QVD, 10 μΜ) and z- VAD-FMK (50 μΜ) or the specific caspase inhibitors z-DEVD-FMK (50 μΜ, caspase 3/7), z-LEHD-FMK (50 μΜ, caspase-8) and z-IETD-FMK (50 μΜ, caspase-9) were added 30 min before inducing PCD.
Protein extraction and immunoblotting.
Cell fractions were lysed in 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 % Triton X- 100 and 1 mM EDTA supplemented with anti-protease and anti-phosphatase cocktails (Roche). The protein concentration was determined using the Bio-Rad DC kit, and 70 μg of protein was loaded in linear SDS-PAGE gels. After blotting, nitrocellulose filters were probed with primary antibodies against CD47 (48), activated caspase-3, PLCyl, and PLCyl-Y783 (Cell Signaling) and a-tubulin. Immunoreactive proteins were detected using HRP-conjugated secondary antibodies and visualised with the ECL system. Immunoblot images were acquired on a Bio-Imaging System MF-ChemiBIS 4.2 (DNR Bio-Imaging Systems). PLCyl-Y783 was quantified using Multi Gauge 3.0 software (Fujifilm Life Sciences). The optical density was normalized to the background and was expressed relative to the untreated cells (set at 1.0).
Electron microscopy.
CLL cells were fixed with 2% glutaraldehyde in phosphate buffer (pH 7.4) for 2 h at RT, washed, and postfixed in 2% Os04 before being embedded in Durcupan® resin. Ultrathin sections stained with uranyl acetate and lead citrate were analyzed with a transmission electron microscope (Carl Zeiss Microimaging).
Ca2+ mobilization assessment. B-cells were loaded for 30 min at 37°C with Fura2- AM and pluronic acid (Invitrogen) in glass bottom dishes (MatTek Corporation), washed in Ringer solution, and activated with PKHB1 or ionomycin (positive control) at the indicated concentrations. Cells were excited at wavelengths 340 and 380 nm. The fluorescence
emissions of several cells were simultaneously recorded at a frequency of lHz using a dual excitation fluorometric imaging system (TILL-Pho tonics). Fluorescence values were analyzed using Origin software (OriginLab Corporation) and were normalized to the first value according to the equation (F/F0)-1, where 'F' is the fluorescence at a specific timepoint and 'F0' is the fluorescence at time 0. Ca2+ curves were normalized to the maximal response elicited by ionomycin. The area under the curve, representing the extent of Ca2+ mobilization, was calculated for each cell and graphed. qRT-PCR.
Total RNA was extracted from normal or CLL B-lymphocytes using the Nucleospin®
RNA II kit (Macherey-Nagel). cDNA was prepared using Superscript® II reverse transcriptase (Life Technologies). Quantitative RT-PCR was performed using TaqMan® Gene Expression Assays (Life Technologies) for CD47, PLCB1 (phospho lipase C, beta 1), PLCB2 (phospho lipase C, beta 2), PLCB3 (phospholipase C, beta 3), PLCB4 (phospho lipase C, beta 4), PLCG1 (phospholipase C, gamma 1), PLCG2 (phospholipase C, gamma 2), ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1), ITPR2 (inositol 1,4,5-trisphosphate receptor, type 2), ITPR3 (inositol 1,4,5-trisphosphate receptor, type 3), RYR1 (ryanodine receptor 1), RYR2 (ryanodine receptor 2), RYR3 (ryanodine receptor 3), STIMl (stromal interaction molecule 1), STIM2 (stromal interaction molecule 2), ORAIl (calcium release-activated calcium modulator 1), ORAI2 (calcium release-activated calcium modulator 2) and ORAI3 (calcium release-activated calcium modulator 3). PCR reactions were performed in triplicate using TaqMan® Universal PCR Master Mix (Life Technologies). The products were amplified in a ViiA7 Real-time PCR System (Life Technologies) at 60°C for 40 cycles. Data were analyzed using the comparative threshold cycle method. The expression of GUSB or ABL (49) was utilized to normalize the data.
PLCyl-Y783 flow cytometry.
At various time points after PKHB1 treatment, 5x105 cells were fixed in ethanol and permeabilized in Triton X-100. Then, cells were saturated in PBS+Triton X-100+10% FCS, incubated with anti-PLCyl-Y783 (Cell Signaling), and detected using an anti-rabbit IgG conjugated with Alexa Fluor 488. The data on the entire cell population were collected on a FACSCanto II flow cytometer. PLCyl-Y783 was quantified based on the mean fluorescence intensity (MFI) for each sample.
IP3 quantification.
IP3 was measured using IP1 as a surrogate (E. Trinquet et al, 2006) with an HTRF assay (Cisbio). The assays were performed in triplicate in 96-well plates, and the signal was quantified on an Ml 000 plate-reader (TEC AN).
Vectors and lentiviral transduction.
To down-regulate PLCyl, we utilized two shRNAs (A: CTGAGAAATACGTGAACAA, SEQ ID NO: 3; B: AGTGAATGCTAGACAGAAA, SEQ ID NO: 4) and a control scrambled shRNA (ACGATAGTCGGTCGATAAA, SEQ ID NO: 5). Forward and reverse oligonucleotides (Invitrogen) were annealed and cloned into the pLVTHM lentiviral vector (Addgene 12247). Virus was produced in 293T cells after the CaC12-mediated transient transfection of the lentiviral constructs and the packaging plasmids pMD2.G and psPAX-2 (Addgene 12259 and 12260, respectively). Forty-eight hours after the transfection, the lentiviral supematants were harvested, clarified by filtration and immediately used to transduce 5x106 primary CLL or MEC-1 cells. At 72 h post-infection, GFP-positive cells were sorted on a FACSVantage cytofiuorimeter (BD Biosciences) to analyze PCD.
CLL xenograft model.
MEC-1 cells (3x106) were injected subcutaneously into NOD scid gamma (NSG) mice (Charles River). When the tumor volume reached 100 mm3, the mice received intraperitoneal injections of PBS, PKHB1, or 4N1K (400 μg in 200 μΐ PBS) once a week. Tumor size was measured with a caliper, and tumor volume was calculated using the formula (length x width2)/2 and expressed in mm3. Alternatively, XenoLight RediJect 2-DG-750 Probe (Caliper) was injected into the sinus retro-orbital to visualize tumor glucose uptake, which reflects cell proliferation. Fluorescence was measured using an in vivo imaging system FX Pro (Kodak), and pictures were analyzed with Carestream MI software. These in vivo studies were approved by the Institutional Animal Care and Use Committee at Bichat hospital.
To determine hemoglobin levels, tumors were excised from euthanized mice, weighed, and homogenized in PBS. After centrifugation, formic acid was added to the supernatant, and the hemoglobin concentration was calculated based on the absorbance at 405 nm.
To assess PCD, calreticulin exposure and PLCyl-Y783, dissociated tumors were digested in medium containing Liberase-TL (Roche), DNase-I (Calbiochem), and
Collagenase-IV (Life technologies). Single-cell suspension, obtained by filtering through a 70 μΜ cell strainer, was analyzed by flow cytometry.
Immunohistochemistry.
Tumor vessels were observed on 5 μιη cryo-sections by targeting mouse CD31 protein. Briefly, sections were pre-treated by blocking endogenous peroxidase with 0.3% H202, and endogenous Avidin/Biotin (Vector labs). Then, sections were incubated with a rat anti-mouse CD31 (BD Biosciences) followed by a goat F(ab')2 anti-rat IgG(H+L)-Biotin (Southern Biotech). mCD31 was visualised with Vectastain Elite ABC kit (Vector labs) plus DAB chromogenic substrate (Interchim). Sections were counterstained with hematoxylin and mounted with ImmunoMount (Thermo Scientific).
Statistical analysis.
Mann- Whitney tests and Student's t-tests were performed using GraphPad Prism software. Except otherwise noted, our assessments included an equal number of stage A and stage B/C CLL patients.
Results Example 1: Efficacy of TSPl-derived peptides that binds CD47 to kill leukemic
CD5+ B-lymphocytes and associated mechanism.
PKHB1, a human-serum stable TSPl-derived peptide that binds CD47, selectively kills leukemic CD5+ B-lymphocytes, including those from individuals with dysfunctional TP53.
To explore the potential of CD47 activation by peptide targeting in primary CLL B- lymphocytes, we first analyzed the triggering with 4N1K. We observed that after only 2 h of treatment with 4N1K, 43% of CLL cells obtained from a cohort of 80 patients were AnnexinV/PI positive (data not shown). This cohort of patients included individuals with positive and adverse prognostic features, including those with CLL Binet Stages B and C classifications, unmutated IGHV, positive ZAP70 and CD38 expression, l lq, 13q, 17p deletions, and trisomy 12 (data not shown). In contrast to 4N1K, the negative control analogue 4NGG was ineffective at inducing cytotoxicity in CLL. Moreover, 4N1K incubation had no effect on the normal B-lymphocytes isolated from healthy donors (data not shown).
The specificity of 4N1K to induce PCD in leukemic cells, but not in normal B-lymphocytes, led us to further investigate the therapeutic potential of 4N1K.
The major weakness in the use of peptides as therapeutic agents is their short in vivo half-life due to protease degradation. Using an HPLC approach, we observed that a 1 h incubation in human serum resulted in more than 90% of the 4N1K peptide being degraded (data not shown). For that reason, we sought to improve 4N1K stability in human serum by replacing, at selected positions, natural L-amino acids by their D-counterparts. The N- and C- terminal lysines of 4N1K, which were introduced to improve solubility, are not related to the CD47 interaction site of the peptide (VVM motif). Therefore, we replaced these two terminal residues with their D-analogues (data not shown). The novel decapeptide, named hereafter PKHB1, was not degraded after long-time incubation in human serum (data not shown), but maintained the solubility and the CD47 link core of 4N1K. Moreover, the induction of PCD in CLL cells with PKHB1 was more potent than with 4N1K, both in terms of concentration level and incubation times (data not shown).
Consequently, we assessed the effect of PKHB1 on B-cells from 20 healthy donors and in our entire cohort of 80 CLL patients. We used PKHB1 at 200 μΜ, a concentration that resulted in similar PCD responsiveness in CLL cells as 300 μΜ of 4N1K. PKHBl-treated CLL cells underwent a rapid cell viability loss (-49% in 2 h). Similarly to 4N1K, PKHB1 had no effect on B-lymphocytes from healthy donors. More significant from a therapeutic perspective, PKHB1 treatment significantly killed the CD5+ tumor B-cells while sparing the residual CD5" B-lymphocytes of the CLL patient (data not shown). These findings reveal that PKHB1 selectively kills the leukemic B-cells.
Because no adapted therapeutic is currently being used to treat CLL refractory patients with dysfunctional TP53, we compared the response of the functional and dysfunctional TP53 CLL cells (data not shown) to PKHB1 and the P53-dependent PCD inducer etoposide.. In cells with a functional TP53, a 24 h etoposide treatment was required to provoke a PCD comparable to that obtained after 2 h incubation with PKHB1. B-lymphocytes with a dysfunctional TP53, which are resistant to etoposide, were killed after 2 h incubation with PKHB1 (data not shown). Thus, targeting CD47 with PKHB1 efficiently killed CLL cells, including those from dysfunctional TP53 individuals.
Next, given that the microenvironment plays a critical role in the progression and drug resistance of tumors, we analyzed whether PKHB1 -mediated PCD is modulated by the presence of either bone marrow stromal cells or sCD40L and IL-4, two anti-apoptotic cytokines generated by lymphoid tissue. Under these conditions, we observed that the
responsiveness of CLL cells to PKHBl remained unchanged (data not shown). In contrast, the induction of PCD by etoposide was significantly diminished. These data confirm that, contrary to other forms of cell death, the PKHBl -mediated killing is not down-modulated by the survival stimuli provided by the lymphocyte microenvironment.
PKHBl induced caspase-independent PCD in CLL cells.
We next assessed the mechanism regulating PKHBl -induced PCD in CLL. In contrast to etoposide-induced caspase-dependent PCD, the features of PKHBl -induced killing, including phosphatidylserine (PS) exposure, cell viability loss, and mitochondrial transmembrane potential (ΔΨηι) disruption, were not prevented by pre-incubation with broad spectrum or specific caspase inhibitors (data not shown). The main effector caspase-3 remained as an inactive pro-enzyme after treatment of CLL cells with PKHBl (data not shown), demonstrating that this CD47 peptide agonist induces caspase-independent PCD. Moreover, PKHBl also provoked in CLL cells a caspase-independent exposure of calreticulin, a pro-phagocytic protein that promotes cell removal. Note that, in contrast to the constitutive expression of calreticulin in acute leukemia cells and solid tumors, this protein was not detected on the surface of untreated CLL cells (data not shown). Thus, PKHBl activated a caspase-independent PCD that enabled dying CLL cells to be recognized and engulfed.
PKHBl provoked PCD in CLL via ER-stress, Ca2+ overload, and mitochondrial damage.
From the above experiments, we learned that PKHBl treatment triggered PCD in leukemic but not in normal B-lymphocytes. As demonstrated by qRT-PCR, immunoblot, and flow cytometry approaches, this different response to PKHBl is not correlated with a different expression level of CD47 (data not shown). Therefore, we searched for a PCD mechanism specifically activated by PKHBl in CLL, but not in normal B-lymphocytes. Because morphological alterations in intracellular organelles correlate with the different forms of PCD , we first performed an ultra-structural analysis of PKHBl -treated normal and CLL B-cells. This approach revealed that PKHBl treatment induced a significant dilation of the ER in leukemic B-lymphocytes (data not shown). The ER plays a key role in modulating Ca2+ mobilization, we therefore considered a potential role of Ca2+ in the PKHBl -mediated PCD. This role was confirmed by pre-treating the CLL cells with the Ca2+ chelator BAPTA prior to incubation with PKHBl This pre-treatment abolished the PKHBl -mediated killing.
Moreover, pre-treatment with BAPTA-AM (intracellular Ca2+ chelator), 2-APB (inositol- 1,4,5-triphosphate ER receptor (IP3R) inhibitor) or dantrolene (ryanodine ER receptor (RyR) inhibitor) significantly decreased PKHB1 -mediated death (data not shown). Altogether, these findings revealed that PKHB1 treatment induces an ER stress, which provokes Ca2+-mediated PCD in the CLL cells.
Next, we compared Ca2+ mobilization in normal and CLL B-lymphocytes. In normal B-cells, PKHB1 triggered a classical Ca2+ signal with a rapid transient increase in intracellular Ca2+ ([Ca2+]i) that returned to baseline (data not shown). In CLL cells, PKHB1 incubation triggered a strong and sustained Ca2+ mobilization, which did not return to basal level (data not shown). Thus, PKHB1 provoked a different Ca2+ mobilization in normal and leukemic cells. Moreover, Ca2+ mobilization and PCD increased in PKHB1 -treated CLL cells in a dose-dependent manner (data not shown). These results provided a direct link between Ca2+ overload and induction of PKHB1 -mediated PCD in CLL.
An important question arising from our above data is how the PKHB1 -induced sustained Ca2+ mobilization affects CLL cell viability. Because regulated Ca2+ entry into mitochondria is required to maintain intracellular Ca2+ homeostasis and avoid PCD, we analyzed whether the sustained Ca2+ mobilization induced by PKHB1 -treatment in CLL affected mitochondria. The pharmacological blockade of the Ca2+ entry into mitochondria with the mitochondrial Ca2+ uniporter (MCU) inhibitor Ru360 moderated the ΔΨιη loss induced by PKHB1 -treatment, precluding PCD. Thus, it seems that the treatment of CLL cells with PKHB1 induced a Ca2+ overload that provoked PCD via mitochondrial damage.
Example 2: Identification of the PLCyl as a signal transduction protein in the mechanism of the TSPl-derived peptides and its usefulness as a biomarker.
PLCyl is over-expressed in CLL with increased expression correlated to disease progression.
To unravel the molecular mechanism responsible for the sustained Ca2+ mobilization leading to PCD in CLL, we performed a quantitative RT-PCR analysis of the major genes involved in the regulation of cellular Ca2+ homeostasis. Out of 17 different genes tested, only PLCyl mRNA was highly expressed in CLL cells compared to normal B-lymphocytes (data not shown). Taking advantage of our important cohort of CLL patients we confirmed that, compared to normal B-cells, the level of PLCyl mRNA was on average more than three times higher in CLL cells compared to normal B-cells (Figure 1 A). This result was fully supported
by protein expression data (data not shown). Because the panel of PLCyl mRNA expression in CLL cells was quite scattered (Figure 1A, right panel), we wondered if there was a correlation between the expression of the PLCyl mRNA and the progression of the disease. The clinical analysis of the CLL patients corroborated that the PLCyl mRNA is more expressed in patients with advanced disease (Binet Stages B/C), than in patients with indolent CLL (Binet Stage A) (Figure IB). This result revealed that the expression of the PLCyl mRNA could be considered as a marker of CLL severity.
Moreover, in the high-risk CLL patients with a deleted ATM gene (del 11 q) or a dysfunctional TP53 gene (placed in the 17p region), the PLCyl mRNA is more expressed than in patients with functional ATM and TP53 genes (Figure 1C). Thus, the expression of PLCyl mRNA could be considered a marker of CLL severity. This is fully supported by the results obtained by measuring the levels of the surrogate CLL marker ZAP70. In the CLL patients with high levels of ZAP70 (bad prognosis), the PLCyl mRNA is more expressed than in patients with low ZAP70 levels (good prognosis) (Figure ID).
ZAP70 (70-kDa zeta-associated protein) is an intracellular tyrosine kinase associated with the B-cell receptor in CLL. The expression of ZAP-70 (> or =20% of B cells) has been associated with an increased risk for an adverse outcome in B-cell CLL and is considered an important risk factor in these patients. ZAP-70 expression, if present, is constant throughout the patient's clinical course and thus is a valid risk marker regardless of when it is evaluated.
The sustained activation of PLCyl controls PKHBl -mediated PCD in CLL.
PLCyl catalyzed the formation of IP3, which binds to its receptors on the ER and, subsequently, triggers store-operated Ca2+ release. PLCyl is over-expressed in CLL; therefore, the disparate Ca2+ mobilization recorded in the PKHBl -treated normal and CLL B- cells could be related to the differential activation of PLCyl . Measuring PLCyl activation by its phosphorylation at Y783, we observed that PLCyl was rapidly phosphorylated before returning to basal levels in the PKHBl -treated normal B-cells. However, PLCyl Y783 phosphorylation in the PKHBl -treated CLL cells remained high for at least 2 h (data not shown). Note that the kinetic of PLCyl phosphorylation matched the kinetic of Ca2+ response measured in normal and CLL B-cells. Next, by measuring IPl production in PKHBl -treated CLL cells, we validated that the sustained PLCyl phosphorylation correlated with the increased catalytic activity of the protein in the CLL B-cells (Figure 2A). Moreover, the IPl production following PKHBl incubation was reduced using the PLC inhibitor U73122
(Figure 2B), emphasizing the correlation between the over-activation of PLCyl triggered by PKHBl and Ca2+ overload measured in CLL cells.. Consequently, the pre-incubation of CLL cells with U73122 prior to PKHBl treatment significantly decreased PCD (Figure 2C).
In addition to the above pharmacological approach, we assessed the role of PLCyl in PKHBl -mediated PCD in primary CLL by using lentiviral down-regulation of PLCyl with two independent shR As. As shown in Figure 2D, the down-regulation of PLCyl desensitized the primary CLL lymphocytes to PKHBl -induced PCD. Overall, these findings confirm the key role of PLCyl in the CD47 peptide targeting-mediated PCD in CLL. Treatment with PKHBl reduced CLL tumor burden in vivo.
Finally, from a therapeutic perspective, we analyzed the in vivo effect of PKHBl on tumor growth of MEC-1 cells in NOD scid gamma (NSG) mice. MEC-1 is an established CLL cell line with dysfunctional TP 53 that is resistant to etoposide but responds to PKHB 1 in exactly the same way as primary CLL cells (data not shown). NSG mice were subcutaneously injected with MEC-1 cells, and the tumors were allowed to grow for 14 days until they reached 100 mm3. The mice were then treated intraperitoneally once a week with the vehicle or PKHBl . After two weeks of treatment, PKHBl -treated, but not vehicle-treated, mice had a significantly decreased tumor growth rate (-50% of tumor volume diminution). However, as could be expected by the instability of the peptide, the 4N1K treatment was unable to reduce tumor volume (data not shown). The analysis of the tumors from the PKHBl- and vehicle- treated mice revealed similar hemoglobin levels within the engrafted tumors, indicating that PKHBl did not provoke anemia (data not shown). Moreover, anti-CD31 labeling performed in tumors from PKHBl- and vehicle-treated mice revealed that the decreased tumor growth rate induced by PKHBl was not a consequence of anti-angiogenic effects (data not shown). Indeed, compared to the vehicle, the mice receiving PKHBl showed increased levels of PLCyl -Y783 phosphorylation (Figure 3), as well as an enhanced calreticulin exposure (data not shown) and a loss of cell viability loss (data not shown) within the engrafted tumors. Together, these findings confirmed that the treatment with PKHBl eliminates CLL cells in vivo by inducing PLCyl -mediated PCD.
Example 3: Soluble peptides agonist of CD47
The structure of 4N1K peptide is as followed:
4N1K is an undecapeptide with the following sequence: K-R-F-Y-V-V-M-W-K-K (SEQ ID NO: l). To improve peptide solubility, stability and pharmacological properties, the 4N1K is modified by chemical modifications that are established on the following 2 models:
Model 1 :
A1-A2-A3-A4-A5-A6-A7-A8-A9-A10
In model peptide 1 , A (1 to 10) correspond to nothing and/or natural amino acids and/or non natural amino acids or amino acids derivatives as for example prolinoamino acids [Mothes C et al, 2008], beta-amino acids [Moumne R et al, 2007], cyclopropylamino acids [Joosten A et al, 2009], N-methylamino acids [Sagan S et al, 2004], and/or alpha-alpha disubstituted amino acids, and/or disubstituted beta-amino acids (Beta2,2, beta3,3 ou beta2,3) and or aza-amino acids (Proulx, C et al, 201 1) or azido lysine [Larregola M et al, 2001]. The absolute configurations of the stereogenic centers are not indicated since all the amino acids are natural amino acids or synthetically obtained amino acids, enantiomerically pur from (L) or (D) series or used as racemate.
For model 2, the absolute configurations of the stereogenic centers are not indicated since all the amino acids are natural amino acids or synthetically obtained amino acids, enantiomerically pur from (L) or (D) series or used as racemate.
The R groups (1 to 10) correspond to amino acids side chains that can be natural or synthetic amino acids side chains. For the glycine residu, this side chain correspond to a hydrogen atom.
PI and P2 correspond to functions respectively on the N-terminal and C-terminal sides of the peptides.
Thus, PI can be an amine function (PI = -NR1 1 , where Rl 1 is a hydrogen atom or an alkyle chain (similar to methyl, ethyl or benzyl), a carboxylic function (PI = -C02H), a carboxamide function (PI = -CONR12R13, where R12 and R13 are hydrogen atoms and/or alkyle chains (similar to methyl, ethyl or benzyl) or an amine function, or an azido function (N3).
Thus, P2 can be an amine function (P2 = -NR1 1 , where Rl 1 is a hydrogen atom or an alkyle chain (similar to methyl, ethyl or benzyl), a carboxylic function (P2 = -C02H), a carboxamide function (P2 = -CONR12R13, where R12 and R13 are hydrogen atoms and/or alkyle chains (similar to methyl, ethyl or benzyl) or an amine function, or an azido function (N3).
Y groups (1 to 10) correspond to hydrogen atoms and/or methyl groups, and/or natural amino acids side chains.
Yl can also be a protecting group such as an acetamide, a benzamide, a benzyloxycarbonyl, a tertbutyloxycarbonyl, a phenylfluorenylmethoxycarbonyl protecting groups.
Peptides and analogues are synthesized by SPPS or LPPS with Boc, Fmoc or Z stategies. The protonation states of all functions (amino groups, carboxylic functions, guanidinium...) is depending on the syntheses and purifications procedures and can be different from the one indicated on the schemes.
I- Short analogues based on model 1 : A1-A2-A3-A4-A5-A6-A7-A8-A9-A10
To improve the solubility and the stability of the octapeptide R-F-Y-V-V-M-W-K (SEQ ID NO:3), the following chemical modifications are realized: a) Mixed salts:
N-methylmorpholine and chlorhydrate or trifluoroacetylcarboxylate mixed salts:
R7 refers to methionine, methionine sulfoxyde, methionine sulfone or alanine or butylglycine or lysine side chain.
A2 refers to lysine or azido lysine or arginine or bis-ornithine [Aussedat B et al, 2006] or bis-arginine or beta-2-homo lysine, or beta-2-homoarginine or beta-2-bis-homoornithine or beta-2-bis-homoarginine. The N- terminal amine function can be free or protected by Boc, Fmoc or Cbz groups, and/or can be N-methylated.
A9 refers to a lysine or arginine or bis-ornithine or bis-arginine or a beta-3- ho mo lysine, or a beta-3-homoarginine or a beta-3-bis-homoornithine or a beta-3-bis- homoarginine. The A9 carboxylic function is free or protected as a carboxamide (P2 = - CONR12R13, where R12 and R13 are hydrogen atoms and/or alkyls groups such as methyl, ethyle, benzyl groups and derivatives).
Free or N-methylated amine functions can be obtained as Chlorhydrate or TFA salts (n is variable, depending on the nature of A2, R7 or A9).
Free carboxylic function can be obtained (but not necessarily) as N-methylmorpholine salts (p = 1).
PKHB3 is an example of peptide from these series where A2 and A9 correspond respectively to beta-2-homoarginine and beta-3 -homo lysine:
Formula (II) b) Tetraphenylborate salts:
R7 corresponds to methionine, methionine sulfoxyde, methionine sulfone or alanine or butylglycine or lysine side chains.
A2 corresponds to lysine or azido lysine or arginine or bis-ornithine or bis-arginine or a beta-2-homo lysine, or a beta-2-homoarginine or a beta-2-bis-homoornithine or a beta-2-bis- homoarginine. The free N-terminal amine function can also be protected by a Boc, Fmoc or Cbz groups, and/or N-methylated.
A9 corresponds to lysine or arginine or bis-ornithine or bis-arginine or beta-3- homolysine, or beta-3-homoarginine or beta-3-bis-homoornithine or beta-3-bis-homoarginine. The carboxylic function of A9 is free or protected as a carboxamide (PI = -CONR12R13, where R12 and R13 are hydrogen atoms and/or alkyl groups such as methyl, ethyl, benzyl derivatives).
The free or N-methylated amine functions are obtained as tetraphenylborate salts, m being variable, depending on A2, R7 or A9.
The structure and the syntheses of the peptides below are given as examples:
The peptides described above are also prepared with N- and C-termini protecting groups. d) Various chemical modifications:
A2-A3-A4-A5-A6-A7-A8-A9
R7 is described above. e) (D)-amino acids :
The introduction of (D)-amino acids in peptide sequences stabilize peptides towards proteolytic degradations and thus enhance its pharmacological properties. (D)-amino acids are introduced on the N terminus and/or on the -terminus and/or instead of one, two, three, four, five, six or seven residus in peptide sequence :
(D)R-F-Y-V-V-M-W-K
R-(D)F-Y-V-V-M-W-K
R-F-(D)Y-V-V-M-W-K
R-F-Y-(D)V-V-M-W-K
R-F-Y-V-(D)V-M-W-K
R-F-Y-V-V-(D)M-W-K
R-F-Y-V-V-M-(D)W-K
R-F-Y-V-V-M-W-(Z))K f) Retro-inverso sequences :
The retro-inverso sequences led to peptides partially or fully modified with (D)-amino acids keeping however the spatial orientations of crucial amino acids side chains. The following peptides are prepared, incorporating some chemical modifications in order to maintain peptide polarity, around diamine and diacid, introduced respectively on the C- terminus and N-terminus sides :
Inverso Peptides :
(D)R-(D)¥-(D)Y-(D)\-(D)\-(D)M-(D)W-(D)K
Retro-inverso peptides :
(D)K-(D)W-(D)M-(D)\-(D)\-(D)Y-(D)¥-(D)R (SEQ IDNO :4)
Azido(D)K-(D)W-(D)M-(D)\-(D)\-(D)Y-(D)¥-(D)R
R4 correspond to methionine or alanine or butylglycine or lysine side chains. g) Some analogues based on model 1 : A1-A2-A3-A4-A5-A6-A7-A8-A9-A10 incorporating modified amino acids:
Al and A10 can correspond to (D)-lysine residus or (D)-arginine residus or beta-2 and/or beta-3 homolysine and/or beta-2 and/or beta-3 homoarginine or beta-2,2 or beta-3,3- homolysine or beta-2,2 or beta-3,3homoarginine. PKHB4 (formula III) is an example from this series where A10 have been re laced by a (D)-Lysine residue:
Formula (III)
PKHB11 is another example of peptide from this series where both Al and A2 residues have been replaced by the beta-2,2 homolysine and a D-lysine has been introduced in C-terminal position of the peptide (see for example PKHB11 (formula (IV))):
Formula (IV)):
A2 can correspond to arginine or lysine residus.
N-methylated amino acids or cyclopropylamino acids can be introduced in the sequence in position A2 and/or A3 and/or A4 and/or A5 and/or A6 and/or A7 and/or A8 and/or A9.
A prolinovaline can be introduced in position A5 and/or A6. PKHB9 (formula (V)) and PKHB10 (formula (VI)) are both example of peptide from this series:
Formula (VI)
A prolinomethionine can be introduced in position A7.
A prolinotryptophane or prolmohomotryptophane can be introduced in position A8.
A prolinolysine can be introduced in position A9.
II- Analogues based on model 2 :
PI is an amine function (PI = -NR11, where Rl 1 is a hydrogen atom or an alkyl chain such as a methyl group for example) or a carboxylic acid (PI = -C02H) or an azido group (N3).
P2 can be an amine function (P2 = -NR11, where Rl 1 is a hydrogen atom or an alkyl chain such as a methyl group for example) or a carboxylic acid (PI = -C02H) or an azido group (N3).
The followin peptide is given as an example:
An azido group is present on the N-terminal side. An azido-lysine with S or R configuration is introduced. The R2 group corresponds to lysine or arginine side chains. R7 group corresponds to methionine side chain, methionine sulfoxyde side chain, methionine sulfone side chain or a methyl, or an n-butyl or lysine side chain. b) Amino acids sequence modifications
- (D) residus:
The introduction of (D)-amino acids in peptide sequences stablize peptides towards proteolytic degradations and thus enhance its pharmacological properties. (D)-amino acids are introduced on the N terminus and/or on the C-terminus and/or instead of one, two, three, four, five, six, seven, eight or nine residus in peptide sequence :
(D)K-R-F-Y-V-V-M-W-K-K
K-(D)R-F-Y-V-V-M-W-K-K
K-R-(D)F-Y-V-V-M-W-K-K
K-R-F-(D)Y-V-V-M-W-K-K
K-R-F-Y-(D)V-V-M-W-K-K
K-R-F-Y-V-(D)V-M-W-K-K
K-R-F-Y-V-V-(D)M-W-K-K
K-R-F-Y-V-V-M-(D)W-K-K
R-R-F-Y-V-V-M-W-(D)K-K
K-R-F-Y-V-V-M-W-K-(D)K
K-R-F-Y-V-V-M-W-K-(Z))R
(D)K-R-F-Y-V-V-M-W-K-(D)K (= peptide PKHB1 , formula (I))
Formula (I)
The retro-inverso sequences lead to peptides partially or fully modified with (D)- amino acids keeping however the spatial orientations of crucial amino acids side chains. The following peptides are prepared, incorporating some chemical modifications in order to maintain peptide polarity, around diamine and diacid, introduced respectively on the C- terminus and N-terminus sides:
Inverso Peptide:
(D)K-(D)R-(D)F-(D)Y-(D)\-(D)\-(D)M-(D)W-(D)K-(D)K
Retro-inverso peptide:
(D)K-(D)K-(D)W-(D)M-(D)\-(D)\-(D)Y-(D)¥-(D)R-(D)K (SEQ ID NO:5)
Specific chemical modifications are introduced in retro-inverso peptide sequence in order to keep peptide polarity. The following peptides are prepared:
Retro-inverso modified peptide
In this peptide, (D)-amino acids are introduced instead of (Z)-amino acids, excepted on the N-terminus and C-terminus where diacide (N- terminus) and diamine (C- terminus) are introduced keeping 4N1K peptide polarity.
Ill- Polymer analogues
Polymers (dimers or trimers) analogues are obtained by reacting the azidopeptides (short or long analo ues) throu h Huisgen type cycloaddition reactions:
For example, trimer analogues are obtained by reacting the azidopeptides (short or long analogues) ith tripropargylamine as followed:
The R group corresponds to sequences of azidopeptides described here above.
REFERENCES:
Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure. Binet JL et al, A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981 Jul 1 ;48(1): 198-206.).
E. Trinquet, M. Fink, H. Bazin, F. Grillet, F. Maurin, E. Bourrier, H. Ansanay, C. Leroy, A. Michaud, T. Durroux, D. Maurel, F. Malhaire, C. Goudet, J. P. Pin, M. Naval, O. Hernout, F. Chretien, Y. Chapleur, G. Mathis, D-myo-inositol 1 -phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. Anal Biochem 358, 126-135 (2006)).
H. Dohner, S. Stilgenbauer, A. Benner, E. Leupolt, A. Krober, L. Bullinger, K. Dohner, M. Bentz, P. Lichter, Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343, 1910-1916 (2000).
J. G. Gribben, How I treat CLL up front. Blood 115, 187-197 (2010)
N. Chiorazzi, M. Ferrarini, B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 21, 841-894 (2003).
Phillips-Mason PJ, Kaur H, Burden-Gulley SM, Craig SE, Brady-Kalnay SM (2011). Identification of phospho lipase C gamma 1 as a protein tyrosine phosphatase mu substrate that regulates cell migration. J Cell Biochem 112 (1): 39-48.
V. Mateo, L. Lagneaux, D. Bron, G. Biron, M. Armant, G. Delespesse, M. Sarfati, CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nat Med 5, 1277-1284 (1999).
Wilde JI, Watson SP. Regulation of phospho lipase C gamma iso forms in haematopoietic cells: why one, not the other? Cell Signal. 2001 Oct;13(10):691-701).
X. W. Zhao, H. L. Matlung, T. W. Kuijpers, T. K. van den Berg, On the mechanism of CD47 targeting in cancer. Proc Natl Acad Sci U S A 109, E2843; author reply E2844-2845 (2012).
Claims
1. An in vitro method for classifying a patient suffering from cancer comprising the steps consisting of i) determining the expression level of PLCyl in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing the stage of the patient according to the expression level of PLCyl .
2. An in vitro method for the prognosis of the survival time of a patient suffering from cancer comprising the steps consisting of i) determining the expression level of PLCyl in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good outcome prognosis when the expression level is lower than the predetermined reference value and a poor outcome prognosis when the expression level is higher than the predetermined reference value.
3. An agonist of the CD47 receptor for use in the treatment of patient suffering of a cancer with a high expression level of PLCyl .
4. An agonist according to claim 3 wherein the agonist is a soluble peptide comprising the amino acids sequence: KRFYVVMWK (SEQ ID NO: l) or a function- conservative variant thereof.
5. A compound which active the PLCyl for use in the treatment of cancer.
6. A therapeutic composition comprising a compound which active the PLCyl for use in the treatment of cancer.
7. An in vitro method according to claim 1 or 2 or an agonist according to claim 3 to 4 or a compound according to claim 5 or a therapeutic composition according to claim 6 wherein the cancer is a B-chronic lymphocytic leukemia (CLL).
8. A method for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound which active the PLCyl
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13306698.5 | 2013-12-11 | ||
EP13306698 | 2013-12-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015086727A2 true WO2015086727A2 (en) | 2015-06-18 |
WO2015086727A3 WO2015086727A3 (en) | 2015-09-24 |
Family
ID=49882996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/077335 WO2015086727A2 (en) | 2013-12-11 | 2014-12-11 | New prognostic method for patients suffering of a cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015086727A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106661593A (en) * | 2016-02-25 | 2017-05-10 | 深圳市体内生物医药科技有限公司 | Immunodeficient mice, manufacturing method thereof and application |
WO2017194627A1 (en) * | 2016-05-10 | 2017-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New compounds and pharmaceutical use thereof in the treatment of cancer |
WO2019005757A1 (en) * | 2017-06-27 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identifying and treating resistance to ctla4 antagonists in leukemia |
US11180552B2 (en) | 2017-12-01 | 2021-11-23 | Seagen Inc. | CD47 antibodies and uses thereof for treating cancer |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816397A (en) | 1983-03-25 | 1989-03-28 | Celltech, Limited | Multichain polypeptides or proteins and processes for their production |
EP0367566A1 (en) | 1988-10-31 | 1990-05-09 | Immunex Corporation | Interleukin-4 receptors |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6043344A (en) | 1995-07-19 | 2000-03-28 | Genetics Institute, Inc. | Human CTLA-8 and uses of CTLA-8-related proteins |
US6569645B2 (en) | 1999-05-14 | 2003-05-27 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US6579520B2 (en) | 1998-05-15 | 2003-06-17 | Genentech, Inc. | IL-17 related mammalian cytokine polypeptides (IL-17E) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014041185A2 (en) * | 2012-09-17 | 2014-03-20 | Ait Austrian Institute Of Technology Gmbh | Colon cancer diagnostic method and means |
-
2014
- 2014-12-11 WO PCT/EP2014/077335 patent/WO2015086727A2/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816397A (en) | 1983-03-25 | 1989-03-28 | Celltech, Limited | Multichain polypeptides or proteins and processes for their production |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0367566A1 (en) | 1988-10-31 | 1990-05-09 | Immunex Corporation | Interleukin-4 receptors |
WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
US6043344A (en) | 1995-07-19 | 2000-03-28 | Genetics Institute, Inc. | Human CTLA-8 and uses of CTLA-8-related proteins |
US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
US6579520B2 (en) | 1998-05-15 | 2003-06-17 | Genentech, Inc. | IL-17 related mammalian cytokine polypeptides (IL-17E) |
US6569645B2 (en) | 1999-05-14 | 2003-05-27 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
Non-Patent Citations (10)
Title |
---|
BINET JL ET AL.: "A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis", CANCER, vol. 48, no. 1, 1 July 1981 (1981-07-01), pages 198 - 206 |
E. TRINQUET; M. FINK; H. BAZIN; F. GRILLET; F. MAURIN; E. BOURRIER; H. ANSANAY; C. LEROY; A. MICHAUD; T. DURROUX: "D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation", ANAL BIOCHEM, vol. 358, 2006, pages 126 - 135 |
H. DOHNER; S. STILGENBAUER; A. BENNER; E. LEUPOLT; A. KROBER; L. BULLINGER; K. DOHNER; M. BENTZ; P. LICHTER: "Genomic aberrations and survival in chronic lymphocytic leukemia", N ENGL J MED, vol. 343, 2000, pages 1910 - 1916 |
J. G. GRIBBEN: "How I treat CLL up front", BLOOD, vol. 115, 2010, pages 187 - 197 |
LE GARFF TAVERNIER ET AL.: "Functional assessment of p53 in chronic lymphocytic leukemia", BLOOD CANCER J., vol. L, no. 2, February 2011 (2011-02-01), pages E5 |
N. CHIORAZZI; M. FERRARINI: "B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor", ANNU REV IMMUNOL, vol. 21, 2003, pages 841 - 894 |
PHILLIPS-MASON PJ; KAUR H; BURDEN-GULLEY SM; CRAIG SE; BRADY-KALNAY SM: "Identification of phospholipase C gamma as a protein tyrosine phosphatase mu substrate that regulates cell migration", J CELL BIOCHEM, vol. 112, no. 1, 2011, pages 39 - 48 |
V. MATEO; L. LAGNEAUX; D. BRON; G. BIRON; M. ARMANT; G. DELESPESSE; M. SARFATI: "CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia", NAT MED, vol. 5, 1999, pages 1277 - 1284 |
WILDE JI; WATSON SP: "Regulation of phospholipase C gamma isoforms in haematopoietic cells: why one, not the other?", CELL SIGNAL., vol. 13, no. 10, October 2001 (2001-10-01), pages 691 - 701 |
X. W. ZHAO; H. L. MATLUNG; T. W. KUIJPERS; T. K. VAN DEN BERG: "On the mechanism of CD47 targeting in cancer", PROC NATL ACAD SCI U S A, vol. 109, pages E2843 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106661593A (en) * | 2016-02-25 | 2017-05-10 | 深圳市体内生物医药科技有限公司 | Immunodeficient mice, manufacturing method thereof and application |
WO2017143894A1 (en) * | 2016-02-25 | 2017-08-31 | 深圳市体内生物医药科技有限公司 | Immunodeficient mouse, preparation method therefor, and application thereof |
WO2017194627A1 (en) * | 2016-05-10 | 2017-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New compounds and pharmaceutical use thereof in the treatment of cancer |
US11759496B2 (en) | 2016-05-10 | 2023-09-19 | Philippe Karoyan | Compounds and pharmaceutical use thereof in the treatment of cancer |
WO2019005757A1 (en) * | 2017-06-27 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identifying and treating resistance to ctla4 antagonists in leukemia |
US11180552B2 (en) | 2017-12-01 | 2021-11-23 | Seagen Inc. | CD47 antibodies and uses thereof for treating cancer |
Also Published As
Publication number | Publication date |
---|---|
WO2015086727A3 (en) | 2015-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10358472B2 (en) | High affinity CD47 analogs | |
AU2017236019B2 (en) | Saposin-a derived peptides and uses thereof | |
US9745357B2 (en) | Peptides used for treating cancers and, in particular, chronic lymphoid leukaemia | |
AU2005211764B2 (en) | Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer | |
CN110475565A (en) | Cartilage is gone back to the nest peptide conjugate and its application method | |
WO2015086727A2 (en) | New prognostic method for patients suffering of a cancer | |
AU2022203604A1 (en) | COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS | |
EP1465927B1 (en) | Bag3 antibodies to be used in research, diagnostics and therapy for cell death-involving diseases | |
WO2012015836A1 (en) | Highly potent peptides to control cancer and neurodegenerative diseases | |
CA2906775A1 (en) | Bh4 stabilized peptides and uses thereof | |
WO2019234751A1 (en) | Ubiquitin high affinity cyclic peptides and methods of use thereof | |
US20230090247A1 (en) | Molecules targeting ras protein | |
JPWO2010084851A1 (en) | Peptides with immunoglobulin binding ability | |
US10233222B2 (en) | Methods, compositions, diagnostics and assays for the treatment of Alzheimer's disease | |
US9593148B2 (en) | DPP8 and DPP9 peptide inhibitors | |
US20230287046A1 (en) | Molecules targeting proteins | |
AU2011203315B8 (en) | Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer | |
WO2014194267A2 (en) | Wnt peptide pharmacophore compositions and methods of use thereof | |
Pople | The role of the hermansky-pudlak protein in lysosome biogenesis | |
WO2004058969A1 (en) | Preventives/remedies for cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14830802 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14830802 Country of ref document: EP Kind code of ref document: A2 |